CN105777633A - Tetrahydroisoquinoline derivative and application thereof - Google Patents
Tetrahydroisoquinoline derivative and application thereof Download PDFInfo
- Publication number
- CN105777633A CN105777633A CN201610009817.4A CN201610009817A CN105777633A CN 105777633 A CN105777633 A CN 105777633A CN 201610009817 A CN201610009817 A CN 201610009817A CN 105777633 A CN105777633 A CN 105777633A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- cycloalkyl
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 223
- 239000003814 drug Substances 0.000 claims abstract description 76
- 238000002360 preparation method Methods 0.000 claims abstract description 41
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 15
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 11
- 208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 10
- 208000008589 Obesity Diseases 0.000 claims abstract description 10
- 235000020824 obesity Nutrition 0.000 claims abstract description 10
- 208000006575 hypertriglyceridemia Diseases 0.000 claims abstract description 9
- -1 compound compound Chemical class 0.000 claims description 156
- 125000000217 alkyl group Chemical group 0.000 claims description 77
- 125000003118 aryl group Chemical group 0.000 claims description 66
- 125000001424 substituent group Chemical group 0.000 claims description 59
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 54
- 125000001072 heteroaryl group Chemical group 0.000 claims description 51
- 125000002769 thiazolinyl group Chemical group 0.000 claims description 51
- 125000000304 alkynyl group Chemical group 0.000 claims description 50
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 50
- 230000000694 effects Effects 0.000 claims description 49
- 210000004185 liver Anatomy 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 43
- 238000006243 chemical reaction Methods 0.000 claims description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims description 39
- 239000001257 hydrogen Substances 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 37
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 36
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 35
- 150000002632 lipids Chemical class 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 35
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 33
- 125000003545 alkoxy group Chemical group 0.000 claims description 32
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 29
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 29
- 239000012453 solvate Substances 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 23
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 21
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 20
- 210000002381 plasma Anatomy 0.000 claims description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 230000007850 degeneration Effects 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 13
- 150000001408 amides Chemical class 0.000 claims description 12
- 230000004060 metabolic process Effects 0.000 claims description 12
- 239000000377 silicon dioxide Substances 0.000 claims description 12
- 125000001544 thienyl group Chemical group 0.000 claims description 12
- 125000001624 naphthyl group Chemical group 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 11
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 10
- 125000005493 quinolyl group Chemical group 0.000 claims description 10
- 208000011580 syndromic disease Diseases 0.000 claims description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 9
- 125000002541 furyl group Chemical group 0.000 claims description 9
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 claims description 8
- 206010022489 Insulin Resistance Diseases 0.000 claims description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
- CTWJWSQXAFDUCV-UHFFFAOYSA-N amino nitrate Chemical compound NO[N+]([O-])=O CTWJWSQXAFDUCV-UHFFFAOYSA-N 0.000 claims description 8
- 239000003638 chemical reducing agent Substances 0.000 claims description 8
- 238000005859 coupling reaction Methods 0.000 claims description 8
- 239000007858 starting material Substances 0.000 claims description 8
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 229950002366 nafoxidine Drugs 0.000 claims description 5
- 125000005936 piperidyl group Chemical group 0.000 claims description 5
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 4
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 4
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 claims description 4
- 239000010238 camphora Substances 0.000 claims description 4
- 229940025250 camphora Drugs 0.000 claims description 4
- 125000003262 carboxylic acid ester group Chemical group [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 claims description 4
- 238000007363 ring formation reaction Methods 0.000 claims description 4
- 125000005504 styryl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 33
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 25
- 102000000853 LDL receptors Human genes 0.000 abstract description 21
- 108010001831 LDL receptors Proteins 0.000 abstract description 21
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 abstract description 21
- 108010028554 LDL Cholesterol Proteins 0.000 abstract description 16
- 230000014509 gene expression Effects 0.000 abstract description 16
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 13
- 235000012000 cholesterol Nutrition 0.000 abstract description 12
- 238000008214 LDL Cholesterol Methods 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract description 4
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 abstract 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 171
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 108
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 60
- 239000002585 base Substances 0.000 description 57
- 238000001819 mass spectrum Methods 0.000 description 56
- 238000003756 stirring Methods 0.000 description 51
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 41
- 238000000605 extraction Methods 0.000 description 38
- 239000000376 reactant Substances 0.000 description 38
- 239000003925 fat Substances 0.000 description 33
- 235000019197 fats Nutrition 0.000 description 32
- 208000035126 Facies Diseases 0.000 description 31
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 30
- 239000007787 solid Substances 0.000 description 29
- 239000008280 blood Substances 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 27
- 108010007622 LDL Lipoproteins Proteins 0.000 description 25
- 102000007330 LDL Lipoproteins Human genes 0.000 description 25
- 238000000746 purification Methods 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000003921 oil Substances 0.000 description 21
- 235000019198 oils Nutrition 0.000 description 21
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 21
- 238000004809 thin layer chromatography Methods 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 238000005406 washing Methods 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 17
- 210000003494 hepatocyte Anatomy 0.000 description 17
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 16
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 231100000240 steatosis hepatitis Toxicity 0.000 description 15
- 208000004930 Fatty Liver Diseases 0.000 description 14
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 150000002148 esters Chemical class 0.000 description 14
- 208000010706 fatty liver disease Diseases 0.000 description 14
- 239000004519 grease Substances 0.000 description 14
- 239000003208 petroleum Substances 0.000 description 14
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000007864 aqueous solution Substances 0.000 description 12
- 150000001721 carbon Chemical group 0.000 description 12
- 238000004440 column chromatography Methods 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 12
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 208000029078 coronary artery disease Diseases 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 10
- 229960002855 simvastatin Drugs 0.000 description 10
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 10
- 239000012279 sodium borohydride Substances 0.000 description 10
- 229910000033 sodium borohydride Inorganic materials 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical group C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 7
- 0 C[U]S(*)(=C)=N[S+](*=C)=N Chemical compound C[U]S(*)(=C)=N[S+](*=C)=N 0.000 description 7
- 229940122392 PCSK9 inhibitor Drugs 0.000 description 7
- 125000004414 alkyl thio group Chemical group 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 7
- 229940093265 berberine Drugs 0.000 description 7
- 208000026106 cerebrovascular disease Diseases 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 235000011121 sodium hydroxide Nutrition 0.000 description 7
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 101150094724 PCSK9 gene Proteins 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- 238000011552 rat model Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 229940126657 Compound 17 Drugs 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 125000000000 cycloalkoxy group Chemical group 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 229940125753 fibrate Drugs 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 210000000582 semen Anatomy 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 229940126142 compound 16 Drugs 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 239000004530 micro-emulsion Substances 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 4
- 239000012053 oil suspension Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229940126586 small molecule drug Drugs 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 3
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 108010018763 Biotin carboxylase Proteins 0.000 description 3
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 3
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 3
- 239000004380 Cholic acid Substances 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 3
- 239000012964 benzotriazole Substances 0.000 description 3
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000010338 boric acid Nutrition 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- 235000019416 cholic acid Nutrition 0.000 description 3
- 229960002471 cholic acid Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000005366 cycloalkylthio group Chemical group 0.000 description 3
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 3
- 125000005945 imidazopyridyl group Chemical group 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 150000004668 long chain fatty acids Chemical class 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003419 tautomerization reaction Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 2
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- FZAGOOYMTPGPGF-UHFFFAOYSA-N Lambertine Chemical compound C1=C2C3=CC4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 FZAGOOYMTPGPGF-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
- 108010044159 Proprotein Convertases Proteins 0.000 description 2
- 102000006437 Proprotein Convertases Human genes 0.000 description 2
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108090000787 Subtilisin Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000004171 alkoxy aryl group Chemical group 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000037058 blood plasma level Effects 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 150000002081 enamines Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960000815 ezetimibe Drugs 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 229960002297 fenofibrate Drugs 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229960003765 fluvastatin Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 229960003627 gemfibrozil Drugs 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 229920001427 mPEG Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 108010094020 polyglycine Proteins 0.000 description 2
- 229920000232 polyglycine polymer Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229960002965 pravastatin Drugs 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000005306 thianaphthenyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- IOQORVDNYPOZPL-VQTJNVASSA-N (5S,6R)-5-(4-chlorophenyl)-6-cyclopropyl-3-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-5,6-dihydro-2H-1,2,4-oxadiazine Chemical compound ClC1=CC=C(C=C1)[C@@H]1NC(=NO[C@@H]1C1CC1)C1=NC(=C(C=C1)N1C=NC(=C1)C)OC IOQORVDNYPOZPL-VQTJNVASSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- NMGLVHXJOMBIJW-UHFFFAOYSA-N 1h-benzimidazole;dihydrochloride Chemical compound Cl.Cl.C1=CC=C2NC=NC2=C1 NMGLVHXJOMBIJW-UHFFFAOYSA-N 0.000 description 1
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
- FRUWMYWEARDNTC-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indole Chemical compound C1C=CC=C2NCCC21 FRUWMYWEARDNTC-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UICBHOXXGLYZJH-UHFFFAOYSA-N 5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium Chemical compound C1=CC=C2CC[N+]3=CC4=CC=CC=C4C=C3C2=C1 UICBHOXXGLYZJH-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- PTDNVRMMBUPVLP-UHFFFAOYSA-N C1CC(C2=NNC3=C2N=CC=C3)=CC1 Chemical compound C1CC(C2=NNC3=C2N=CC=C3)=CC1 PTDNVRMMBUPVLP-UHFFFAOYSA-N 0.000 description 1
- IXEPCAMIVCTJJM-UHFFFAOYSA-N C1CN1N1CCC1 Chemical compound C1CN1N1CCC1 IXEPCAMIVCTJJM-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000113306 Monascus purpureus Species 0.000 description 1
- 235000002322 Monascus purpureus Nutrition 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 101800000021 N-terminal protease Proteins 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229940123185 Squalene epoxidase inhibitor Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- NRAINUFKKPBZQY-UHFFFAOYSA-N [O]C1CC1 Chemical compound [O]C1CC1 NRAINUFKKPBZQY-UHFFFAOYSA-N 0.000 description 1
- GYAPJISEIGCPQO-UHFFFAOYSA-N [O]C1CCC1 Chemical compound [O]C1CCC1 GYAPJISEIGCPQO-UHFFFAOYSA-N 0.000 description 1
- DWDAZFJBSZTCCM-UHFFFAOYSA-N [O]C1CCCCC1 Chemical compound [O]C1CCCCC1 DWDAZFJBSZTCCM-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960003526 acipimox Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical group 0.000 description 1
- 125000005262 alkoxyamine group Chemical group 0.000 description 1
- 125000005257 alkyl acyl group Chemical group 0.000 description 1
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- FZZIXIYLIAIOOE-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1.C1=CC=CC2=CC=CC2=C1 FZZIXIYLIAIOOE-UHFFFAOYSA-N 0.000 description 1
- 229960001264 benfluorex Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CJAVTWRYCDNHSM-UHFFFAOYSA-N benzoic acid 2-[1-[3-(trifluoromethyl)phenyl]propan-2-ylamino]ethyl ester Chemical compound C=1C=CC=CC=1C(=O)OCCNC(C)CC1=CC=CC(C(F)(F)F)=C1 CJAVTWRYCDNHSM-UHFFFAOYSA-N 0.000 description 1
- FBOSKQVOIHEWAX-UHFFFAOYSA-N benzothiazine Chemical compound C1=CC=C2N=CCSC2=C1 FBOSKQVOIHEWAX-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- OJVABJMSSDUECT-UHFFFAOYSA-L berberin sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 OJVABJMSSDUECT-UHFFFAOYSA-L 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 229940107218 chromium Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- VRSRXLJTYQVOHC-YEJXKQKISA-N corydaline Chemical group C=1([C@H]2[C@H]3C)C=C(OC)C(OC)=CC=1CCN2CC1=C3C=CC(OC)=C1OC VRSRXLJTYQVOHC-YEJXKQKISA-N 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical group C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940013688 formic acid Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000001261 hydroxy acids Chemical group 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 208000016332 liver symptom Diseases 0.000 description 1
- 108010030696 low density lipoprotein triglyceride Proteins 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N ornithyl group Chemical group N[C@@H](CCCN)C(=O)O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229960004016 sucrose syrup Drugs 0.000 description 1
- XIUROWKZWPIAIB-UHFFFAOYSA-N sulfotep Chemical compound CCOP(=S)(OCC)OP(=S)(OCC)OCC XIUROWKZWPIAIB-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 108010002139 very low density lipoprotein triglyceride Proteins 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/5765—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided are a tetrahydroisoquinoline derivative and an application thereof. The invention relates to a compound represented by the formula (V) and a preparation method and an application thereof in medicines. In particular, the invention relates to the derivative of the compound represented by the general formula (V) and a preparation method and the application thereof as a therapeutic agent in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, type-II diabetes, hyperglycemia, obesity or insulin resistance syndromes and metabolic syndromes. The compound disclosed by the invention also can reduce total cholesterol, LDL-cholesterol and triglycerides, and increases the expression of hepatic LDL receptors and inhibits the expression of PCSK9.
Description
Technical field
The technology of the present invention relates to treatment hyperlipemia (including hypertriglyceridemia and hypercholesterolemia), fatty degeneration of liver, type ii diabetes, hyperglycemia, insulin resistance, obesity, Metabolic syndrome is sought peace the purposes of cancer, compound and compositions.
Background technology
Metabolism syndrome (MetabolicSyndrome, MS) is the pathological state of multiple Metabolite abnormal aggregation, is a complex set of metabolism disorder disease group, is cause diabetes, the risk factor of cardiovascular and cerebrovascular disease.
Cardiovascular and cerebrovascular disease is the number one killer of harm human health, its cause of disease is extremely complex, hyperlipidemia receives again the concern of most people as its very crucial risk factor, and along with the acceleration of the improvement of living standard and aging, the incidence rate of hyperlipidemia and mortality rate are obviously improved, more having pertinent literature to report, dyslipidemia is the main cause causing atherosclerosis, coronary heart disease, myocardial infarction etc..
Hyperlipidemia is often interpreted: the metabolism of fat or operating make one or more lipids in blood plasma be higher than normal extremely.And hyperlipidemia is the disease of kind of general, being often referred in serum T-CHOL (TC), triglyceride (TG) is too high or HDL-C (HDL-C) is too low, and modern medicine is referred to as dyslipidemia.Lipid is to be insoluble or poorly soluble in water, so lipoprotein must be formed with protein bound, therefore, hyperlipidemia is also commonly referred to as hyperlipoproteinemia.
Hyperlipidemia and cerebral infarction: Blood Cholesterol increases and easily forms arteriosclerosis plaque, when these specklees are piled up in arterial wall, can make tremulous pulse official jargon narrow, blocks blood and flows into corresponding position, will cause kinetic energy defect.When it occurs to cause cerebral infarction when cerebrovascular, medical evidence: long-term Lipid modulating can not only treat cerebral infarction, moreover it is possible to prevention cerebral infarction.
Hyperlipidemia and coronary heart disease: coronary heart disease is also called coronary atherosclerotic heart disease.Coronary artery is to the major arteries of heart blood supply, if excess fat deposition, will cause arteriosclerosis, so that blood flow is obstructed, cause heart ischemia, a series of symptom occur, i.e. coronary heart disease.The risk factor causing coronary heart disease is a lot, such as hyperlipidemia, smoking, obesity, hypertension, shortage physical exertion, diabetes, familial history of coronary artery disease etc., wherein, hyperlipidemia be again one of important risk factor causing coronary heart disease.So preventing and treating the most basic therapy of coronary heart disease is regulate blood fat, research shows that in serum, total cholesterol level declines 1%, then coronary heart disease incidence rate declines 2%.The long-term incidence rate and the mortality rate that coordinate Lipid modulating can reduce the angina pectoris of coronary heart disease, myocardial infarction etc..
Hyperlipidemia and fatty liver: fatty liver refers to that fat caused by a large amount of accumulation, often increases with blood fat in liver.Pathogenesis of fatty liver rate is up to 5-10%, and in adult body, Cyklokapren increased perosn about 35% is fatty liver, and part severe patient can develop into liver cirrhosis.Therefore, fatty liver treatment also should carry out adjusting the treatment of fat.
Hyperlipidemia and diabetes: hypertension, hyperlipidemia and hyperglycemia are commonly referred to as " three high ", be the principal element threatening diabetics healthy.Three is closely related, hyperlipidemia can increase the weight of the symptom of diabetes, most of diabeticss are with hyperlipidemia, more it is easily caused apoplexy, coronary heart disease, limb necrosis, retinopathy, nephropathy, neuropathy etc., therefore diabetics is wiped out and treated insect pests and plant diseases outside treatment hyperglycemia, should also be noted that Adjust-blood lipid, this is extremely important for reducing diabetics mortality rate and disability rate.
Hyperlipidemia is defined as blood fat disorder or dyslipidemia.It is often referred to blood in human body in lipid concentration beyond normal range.Raising including triglyceride (TG), serum total cholesterol (TC), C-VLDL (VLDL-C) or low-density lipoprotein cholesterol (LDL-C) level and HDL-C (HDL-C) level reduces along with the further investigation of hyperlipidemia Yu cardiovascular disease, people start to recognize that the risk reducing cardiovascular disease is had very important significance by blood fat reducing.
Blood lipid-lowering medicine conventional currently on the market mainly has Statins, fibrates, nicotinic acid class, cholic acid chelating agent class etc..
Statins represents medicine: atorvastatin, simvastatin, lovastatin, pravastatin, fluvastatin etc..This kind of medicine is development in recent years ratio fat-reducing medicament faster, is mainly the activity of rate-limiting enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase suppressed in serum total cholesterol (TC) route of synthesis, reduces TC synthesis;Low density lipoprotein receptor quantity is increased, accelerates LDL degraded, increase HDL content simultaneously, be conducive to removing and the transhipment of TC.
Weak point: its side effect brought is inevitable, as: rhabdomyolysis, the various enzymatic activity enhancings etc. of myositis and liver, some patients are additionally had to fail to well adapt to the treatment of statins, it is often more important that single Statins treatment also tends to reach intended ideal effect.
Fibrates represents medicine: clofibrate, gemfibrozil, FENOBRATE top grade.Such medicine is through long-term clinical practice, the medicine of the Regulation serum lipids have proven to a class better tolerance, having had.Its blood fat reducing approach also has the activity increasing lipoprotein lipase except similar with Statins, makes the removing of triglyceride (TG) increase;Reduce blood glucose, so that second coenzyme A and free fatty trend towards the synthesis of glucose, make lipid synthesis reduce.
Weak point: untoward reaction often occurs in digestive tract, there is anaphylaxis in occasional, and visual disorder, owing to such medicine adds cholesterol concentration in bile, so being also possible to cause cholelithiasis.
Nicotinic acid class represents medicine: nicotinic acid, inositol niacinate, acipimox etc..The formation of this kind of medicine decomposition and free fatty mainly through suppressing fat, it is suppressed that liver synthetic glycerine three ester (TG) and very low density lipoprotein (VLDL) (VLD-L) reduce blood fat.
Weak point: diabetics effect for reducing blood fat is inconspicuous, side effect such as liver poisoning, the untoward reaction such as hyperglycemia is comparatively obvious, skin epidemic disease often occurs, pruritus.
Cholic acid chelating agent class represents medicine: Ezetimibe (Ezetimibe), how rare unsaturated fatty acid etc..This kind of fat-reducing medicament can be divided into cholesterol absorption inhibitor and how rare unsaturated fatty acid two class.
(1), cholesterol absorption inhibitor (Ezetimibe): be combined with bile acid, hinder the heavily absorption of bile acid, thus promoting cholesterol to be converted into bile acid, combining at intestinal and this medicine and excreting.
(2), polyene unsaturated fatty acid: be combined into esters with cholesterol, promote cholesterol degradation be bile acid with bile excretion so that the concentration of blood bavin T-CHOL reduces.
Low density lipoprotein, LDL (LDL) level crosses high energy atherogenicity, reduces plasma LDL levels and prevention and treatment cardio-cerebrovascular diseases are had great importance.In blood, the LDL of about 70% is that the endocytosis mediated by low density lipoprotein receptor (LDLR) completes to remove, the expression of LDLR is subject to the impact of proprotein convertase subtilisin/kexin9 type (proproteinconvertasesubtilisin/kexintype9) (PCSK9), PCSK9 is a serine protease, main in liver synthesis, it can reduce LDLR quantity in hepatocyte.After PCSK9 and the LDLR being positioned at cell surface is combined, internalization, to cell, promotes LDLR degraded in lysosome.The activity suppressing PCSK9 can increase LDLR quantity, reduces LDL level in blood plasma.
The exploitation of PCSK9 inhibitor is the important directions that current large-scale transnational drugmaker makes great efforts research and development Novel cardiovascular disease medicament, expects that this kind of medicine surmounts the fat-reducing medicament that Statins is ripe.Big drug firm promotes PCSK9 inhibitor medicaments development just underway, current research work is concentrated mainly on the exploitation (such as following table) of biological medicine (including protein drug and long nucleic acid medicine), biological medicine and small-molecule drug are for when treating same disease, biological medicament has with high costs, the shortcomings such as limited preparation way such as ejection preparation can only be adopted, at present, clinical candidates is become but without little molecule PCSK9 inhibitor.
Disclose the micromolecular compound patent application of a series of PCSK9 inhibitor at present, including WO2010075469, WO2011006000, WO2011051961, WO2011152508, WO2012090220, JP2013136572, WO2013132509, WO2013137371, WO2014017569, WO2014002105, WO2014002106, WO2014150326, WO2014150395, WO2014139008 etc..
Although having been disclosed for a series of compound having and suppressing PCSK9 expression and lipid-lowering effect at present, but, need nonetheless remain for that exploitation is new has better drug effect, medicine is for the compound of result, through being continually striving to, present invention design has a compound of logical formula V structure and discovery has the compound of this class formation and shows effect and the effect of excellence, in a wider context, more deeply and all sidedly disclose and illustrate structure and the relation of activity usefulness, there is important using value.
Summary of the invention
It is an object of the invention to provide compound shown in a kind of logical formula V and their tautomer, enantiomer, diastereomer, raceme and pharmaceutically useful salt, and metabolite and metabolic precursor thereof or prodrug.The compound of Formula V
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof;Wherein:
A is nitrogen-atoms, or carbon atom;
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10Selected from hydrogen, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ",-OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, the substituent group of heterocyclic radical or cycloheteroalkylalkyl is replaced;Or R4And R5It is directly connected to by chemical bond;
R11, R12, R13, R14, R15Hydrogen independently, halogen, that be substituted or be unsubstituted silica-based, amino, nitro, oxygen base, sulfenyl, sulfuryl, cyano group, carbonyl, sulfonyloxy, phosphorus acyloxy, alkyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl;
M=0,1,2;
N=1,2,3;
Q=0,1,2,3,4;
T=0,1,2,3.
The present invention relates to general formula compound compound (V), its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, including general formula compound (VI),
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, wherein:
A is nitrogen-atoms, or carbon atom;
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10Selected from hydrogen, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ",-OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, the substituent group of heterocyclic radical or cycloheteroalkylalkyl is replaced;Or R4And R5It is directly connected to by chemical bond;
R11, R12, R13, R14, R15, R16, R17Hydrogen independently, halogen, that be substituted or be unsubstituted silica-based, amino, nitro, oxygen base, sulfenyl, sulfuryl, cyano group, carbonyl, sulfonyloxy, phosphorus acyloxy, alkyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl;
M=0,1,2;
N=1,2,3;
Q=0,1,2,3,4.
The present invention relates to general formula compound compound (VI), its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, wherein, R11, R12, R13, R14, R15, R16, R17It is-H independently, halogen, alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl;
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10It is-H independently, halogen ,-OH ,-NO2,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ;-OC (O) OR ' ,-OC (O) NR ' R ", replacement or the amino that is unsubstituted, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl, be further selected from including:
R27Selected from phenyl, C1-12Alkyl, ring (C3-8) alkyl, thienyl, furyl, imidazole radicals, pyridine radicals, pyrimidine radicals, pyridazinyl, quinolyl, isoquinolyl, phenylacetylene base, benzyl, styryl, naphthyl, substituted-amino, morpholinyl, piperidyl, N methyl piperazine base, nafoxidine base, hexahydropyridine base, Camphora alkyl, p-methylphenyl
Wherein, C1-6Alkyl is optionally replaced by 0 to 13 substituent group,
Thienyl, furyl and imidazole radicals are optionally replaced by 0 to 3 substituent group,
Pyridine radicals is optionally replaced by 0 to 4 substituent group,
Pyrimidine radicals and pyridazinyl are optionally replaced by 0 to 3 substituent group,
Phenyl is optionally replaced by 0 to 5 substituent group,
Quinolyl and isoquinolyl naphthyl are selected for a post and are replaced by 0 to 6 substituent group,
Naphthyl is selected for a post and is replaced by 0 to 7 substituent group,
Above substituent group is selected from: hydroxyl, halogen, cyano group, nitro ,-COOH, carboxylic acid ester groups, replace or be unsubstituted silica-based, amino, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl;
R28Selected from hydrogen, the alkyl replacing or being unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl.
The present invention relates to general formula compound compound (V), its stereoisomer, its tautomer, its solvate and medicinal acceptable salt, wherein R4And R5It is directly connected to by chemical bond, including general formula compound (VII),
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, wherein:
A is nitrogen-atoms, or carbon atom;
R1, R2, R3, R6, R7, R8, R9, R10Selected from hydrogen, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ",-OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, the substituent group of heterocyclic radical or cycloheteroalkylalkyl is replaced;
R11, R12, R13, R14, R15Hydrogen independently, halogen, that be substituted or be unsubstituted silica-based, amino, nitro, oxygen base, sulfenyl, sulfuryl, cyano group, carbonyl, sulfonyloxy, phosphorus acyloxy, alkyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl;
M=0,1,2;
N=1,2,3;
Q=0,1,2,3,4;
T=0,1,2,3.
The present invention relates to general formula compound compound (V), its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, including general formula compound (VIII),
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, wherein:
A is nitrogen-atoms, or carbon atom;
R1, R2, R3, R6, R7, R8, R9, R10Selected from hydrogen, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ",-OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, the substituent group of heterocyclic radical or cycloheteroalkylalkyl is replaced;
R11, R12, R13, R14, R15, R16, R17Hydrogen independently, halogen, that be substituted or be unsubstituted silica-based, amino, nitro, oxygen base, sulfenyl, sulfuryl, cyano group, carbonyl, sulfonyloxy, phosphorus acyloxy, alkyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl;
M=0,1,2;
N=1,2,3;
Q=0,1,2,3,4.
The present invention relates to general formula compound compound (VIII), wherein, R11, R12, R13, R14, R15, R16, R17It is-H independently, halogen, alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl;
R1, R2, R3, R6, R7, R8, R9, R10It is-H independently, halogen ,-OH ,-NO2,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ;-OC (O) OR ' ,-OC (O) NR ' R ", replacement or the amino that is unsubstituted, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl, be further selected from including:
R27Selected from phenyl, C1-12Alkyl, ring (C3-8) alkyl, thienyl, furyl, imidazole radicals, pyridine radicals, pyrimidine radicals, pyridazinyl, quinolyl, isoquinolyl, phenylacetylene base, benzyl, styryl, naphthyl, substituted-amino, morpholinyl, piperidyl, N methyl piperazine base, nafoxidine base, hexahydropyridine base, Camphora alkyl, p-methylphenyl
Wherein, C1-6Alkyl is optionally replaced by 0 to 13 substituent group,
Thienyl, furyl and imidazole radicals are optionally replaced by 0 to 3 substituent group,
Pyridine radicals is optionally replaced by 0 to 4 substituent group,
Pyrimidine radicals and pyridazinyl are optionally replaced by 0 to 3 substituent group,
Phenyl is optionally replaced by 0 to 5 substituent group,
Quinolyl and isoquinolyl naphthyl are selected for a post and are replaced by 0 to 6 substituent group,
Naphthyl is selected for a post and is replaced by 0 to 7 substituent group,
Above substituent group is selected from: hydroxyl, halogen, cyano group, nitro ,-COOH, carboxylic acid ester groups, replace or be unsubstituted silica-based, amino, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl;
R28Selected from hydrogen, the alkyl replacing or being unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl.
The present invention relates to logical formula V compound, this compound is selected from following compound, but is not limited to following compound range:
Or its medicinal acceptable salt.
The present invention relates to the compound shown in logical formula V, its stereoisomer, its tautomer, the method for its solvate and medicinal acceptable salt thereof, it comprises the following steps:
Above syntheti c route describes as follows: X1 and X2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.X1 and X2, under certain reaction condition, obtains compounds X 3 by certain amide method of attachment, and what intermediate X 3 was reacted under the effect of dehydrant obtains X4, in intermediate X 4, carbon-to-nitrogen double bon is after reducing agent effect, nitrogen-atoms occurs coupled reaction to obtain compound V further, wherein A, R1~R15, q, described in t literary composition as defined above.
The present invention relates to the compound shown in formula (VII), its stereoisomer, its tautomer, the method for its solvate and medicinal acceptable salt thereof, it comprises the following steps:
Above syntheti c route describes as follows: Y1 and Y2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.Y1 and Y2 is under certain reaction condition, compound Y3 is obtained by amide method of attachment, what intermediate Y3 reacted under the effect of dehydrant obtains Y4, in intermediate Y4, carbon-to-nitrogen double bon is after reducing agent effect, the further coupled reaction of nitrogen-atoms obtains compound Y5, intermediate Y5 occur further point in cyclization be obtained by reacting compound VII, wherein A, R1~R4, R6~R15, q, described in t literary composition as defined above.
The present invention relates to compound shown in logical formula V, a kind of pharmaceutical composition of preparation, its compound comprising any one and pharmaceutically acceptable carrier.
The present invention relates to a kind of pharmaceutical composition of the composition of compound shown in logical formula V, described compositions includes the compound giving any one of the effective therapeutic dose of patient of needs treatment.
The present invention relates to any one compound purposes in the medicine of the lipid levels prepared for reducing patients blood plasma and/or liver in compound shown in logical formula V.
The present invention relates in compound shown in logical formula V any one compound in preparation for treating hyperlipemia, hypercholesterolemia, hypertriglyceridemia, fatty degeneration of liver, metabolism syndrome, the purposes in disease that cancer is constituted or the medicine of the patient's condition.
The present invention relates to any one compound in compound shown in logical formula V and express and/or reduce the purposes in the PCSK9 medicine expressed in preparation for increasing LDLR.
The present invention relates to compound shown in logical formula V, compound disclosed by the invention has the advantages that
1, disclosed by the invention have logical formula V micromolecular compound, is suppressing PCSK9 gene expression, is increasing the expression of cell LDLR, strengthens hepatocyte to the remarkable effect in the picked-up ability of LDL, is expected to become a new generation's lipid lowerers.
PCSK9 inhibitor is the important directions that current large-scale transnational drugmaker makes great efforts research and development Novel cardiovascular disease medicament as the exploitation of fat-reducing medicament, expects that this kind of medicine surmounts the fat-reducing medicament that Statins is ripe.Big drug firm promotes PCSK9 inhibitor medicaments development just underway, current research work is concentrated mainly on the exploitation of biological medicine (including protein drug and long nucleic acid medicine), at present, clinical candidates is become but without little molecule PCSK9 inhibitor.Such as following table:
Biological medicine and small-molecule drug are for when treating same disease, biological medicament has with high costs, the shortcomings such as limited preparation way such as ejection preparation can only be adopted, and small-molecule drug has cheap for manufacturing cost, the advantages such as formulation method is various, disclosed by the invention have logical formula V micromolecular compound, shows significant suppression PCSK9 gene expression at cellular level, strengthen hepatocyte to the remarkable effect in the picked-up ability of LDL, be expected to become there is lipid lowerers of new generation.On the other hand, the formulation protocol of small-molecule drug selects face more extensive than biopharmaceutical macromolecular drug, is conducive to the exploitation of the multiple drug form of later stage drug development, compares biopharmaceutical macromolecular drug, can be supplied to as preparation type widely, meet the demand of people.
2, with existing patent documentation disclosed in the PCSK9 Compound Phase ratio of target spot for effect, disclosed by the invention have logical formula V compound, novel structure, it is expected to become the drug candidate that PCSK9 is had the novel mechanism of action, and eventually becomes a new generation there is the fat-reducing medicament of novel mechanism of action.
Existing patent document reports a few class and acts on the micromolecular compound of PCSK9 target spot, is summarized as follows with patent applicant's classification:
A, CVIPharmaceuticalLimited apply for a patent WO2010075469, WO2011006000 reports the micromolecular compound obtained based on natural product corydaline structure of modification, such is based on the micromolecular compound of Structures of Natural Products, its manufacturing process is complicated, partial synthesis method needs to use the chemical reagent of severe toxicity, brings bigger harm can to operator and natural environment.
B, CadilaHealthcareLimited apply for a patent WO2011051961, WO2012090220, WO2013132509, WO2014002105, reporting a few micromolecular compound in WO2014002106, these a few micromolecular compounds mainly contain a common chemical constitution fragment hexahydro pyrans methylamino structure fragment in molecular structure feature.This structure fragment is likely to play important role in compound structure with biological activity.
C, KowaCompanyLimited apply for a patent WO2011152508, JP2013136572, WO2013137371, WO2014017569 reports a few micromolecular compound, this kind of micromolecular compound molecular structure relative complex, general embodiment compound is possibly together with three chiral centres, and its manufacture difficulty is relatively large, and embodiment compound is it is generally required to six step chemical reactions (not including the structure of the structure fragment containing chiral centre) just can prepare target compound.
nulld、AmorchemHoldingsINC. apply for a patent in WO2014139008 and report small molecule compound,The section Example compound main structure of such micromolecular compound is in that containing " borate and boric acid " structure fragment,Although having listed multiple myeloma medicine bortezomib (containing " boric acid " structure fragment) at present,But " boric acid class " medicine is at non-therapeutic field of tumor (such as: diabetes,Hyperlipemia etc.) application nevertheless suffer from restriction,Main reason is that the potential neurotoxic side effects of boracic medicine,And its potential chemical characteristic (Chem.Res.Toxicol. with living organism " irreversible fixation ",2013,26(4),pp608–615),Potential " carcinogenecity " being likely to result in SARS drug design of this chemical characteristic," genotoxicity " has extensively been subject to the attention of Pharmaceutical Chemist.
E, ShifaBiomedicalCorporation apply for a patent WO2014150326, WO2014150395 reports two micromolecular compounds, the preparation method relative complex of these micromolecular compounds, the preparation of the compound that some expression activitiy is outstanding needs to use heavy metal catalyst reaction, and uses isocyanate compound.
Summarized above is exactly with the PCSK9 micromolecular compound being action target spot in current disclosed document.Compound disclosed by the invention is equally with PCSK9 for action target spot, and this compounds is all likely to become the newtype drug of following Based PC SK9 action target spot with a few micromolecular compounds of above-mentioned summary.
With existing patent documentation disclosed in the PCSK9 Compound Phase ratio of target spot for effect, disclosed by the invention have logical formula V compound, novel structure, there is brand-new unique structural feature, imply that the molecular structure feature of its novelty of compound disclosed by the invention, likely bring unexpected " quasi-medicated property feature ", be expected to become the drug candidate that PCSK9 is had the novel mechanism of action, and eventually become a new generation there is the fat-reducing medicament of novel mechanism of action..
3, disclosed by the invention have logical formula V compound have activation the kinase whose activity of AMPK, prompting the compounds of this invention not only can be developed into a new generation's lipid lowerers, and the effect better controlling blood glucose can be played, in blood fat reducing and blood sugar lowering, obtain the existing single drugs with function more advantage of comprehensive benefit ratio for vast Metabolic Syndrome Patients.
General formula compound disclosed by the invention (V) preparation is prepared essentially according to following scheme:
Above syntheti c route describes as follows: X1 and X2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.X1 and X2, under certain reaction condition, obtains compounds X 3 by certain amide method of attachment, and what intermediate X 3 was reacted under the effect of dehydrant obtains X4, in intermediate X 4, carbon-to-nitrogen double bon is after reducing agent effect, nitrogen-atoms occurs coupled reaction to obtain compound V further, wherein A, R1~R15, q, described in t literary composition as defined above.
Further, formula (VII):
Above syntheti c route describes as follows: Y1 and Y2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.Y1 and Y2 is under certain reaction condition, compound Y3 is obtained by amide method of attachment, what intermediate Y3 reacted under the effect of dehydrant obtains Y4, in intermediate Y4, carbon-to-nitrogen double bon is after reducing agent effect, the further coupled reaction of nitrogen-atoms obtains compound Y5, intermediate Y5 occur further point in cyclization be obtained by reacting compound VII, wherein A, R1~R4, R6~R15, q, described in t literary composition as defined above.
Accompanying drawing illustrates:
After Fig. 1 shows compound treatment, the fluorescence intensity that basis of microscopic observation arrives is evaluated sample and hepatocyte is absorbed the impact of LDL ability.
Fig. 2 shows high fat SD rat, is administered after surrounding through part of compounds oral administration gavage of the present invention, and in serum, the measurement result of low-density lipoprotein cholesterol (LDL-C) compares.
Fig. 3 shows high fat SD rat, is administered after surrounding through part of compounds oral administration gavage of the present invention, and in serum, the measurement result of T-CHOL (TC) compares.
Fig. 4 shows high fat SD rat, is administered after surrounding through part of compounds oral administration gavage of the present invention, and in serum, the measurement result of glutamate pyruvate transaminase (ALT) compares.
Fig. 5 shows high fat SD rat, is administered after surrounding through part of compounds oral administration gavage of the present invention, and in serum, the measurement result of glutamic oxaloacetic transaminase, GOT (AST) compares.
Detailed Description Of The Invention
In many aspects, present technology provides the compound of novelty and the purposes that this compound is in reducing the purposes of lipid levels of blood plasma and/or liver and treatment hyperlipemia, hypercholesterolemia, hypertriglyceridemia, fatty degeneration of liver, type ii diabetes, hyperglycemia, insulin resistance, obesity and metabolism syndrome.Compound provided herein can be formulated for the pharmaceutical composition in method disclosed herein and medicament.Present invention also offers described compound for preparing the purposes of pharmaceutical formulation and medicament, described compound purposes in the lipid levels reducing blood plasma and/or liver and described compound are in treatment hyperlipemia, hypercholesterolemia, hypertriglyceridemia, fatty degeneration of liver, type ii diabetes, hyperglycemia, the purposes in insulin resistance, obesity and metabolism syndrome.
Following term herein in the whole text in use according to following definitions.
Generally, mention certain element, for instance hydrogen or H, represent all isotopes including this element.Such as, if R group is defined to include hydrogen or H, it also includes deuterium and tritium.Comprise radiosiotope (such as tritium, C14、P32And S35) compound therefore also in the scope of the present invention.For by this type of labelling insert the present invention compound in means be that those skilled in the art are apparent based on disclosure herein.
Generally, " being substituted " represents such organic group (such as alkyl) as defined below, and the key of the connected non-hydrogen atom of the key of the one or more connection hydrogen wherein contained or non-carbon is replaced.The group being substituted also includes such group: wherein one or more keys connecting carbon atom or hydrogen atom are replaced by the heteroatomic key of one or more connections (including double or triple bonds).Thus, unless otherwise, the group being replaced is replaced by one or more substituent groups.In some embodiments, substituent group is replaced by 1,2,3,4,5 or 6 substituent groups.(namely the example of substituent group includes halogen, F, Cl, Br and I), hydroxyl, alkoxyl, alkene oxygen base, aryloxy, aralkyl oxy, heterocyclyloxy and heterocyclylalkoxy, carbonyl, carboxyl, ester, carbaminate/ester, oxime, hydroxylamine, alkoxyamine, aralkoxy amine, sulfur alcohol, sulfide, sulfoxide, sulfone, sulfonyl, sulfonamide, amine, N-oxide, hydrazine, hydrazides, hydrazone, azide, amide, urea, amidine, guanidine, enamine, acid imide, isocyanates/ester, isothiocyanate/ester, cyanate/ester, thiocyanate/ester, imines, nitro, nitrile etc..
The ring base being substituted, for instance cycloalkyl, aryl, heterocyclic radical and the heteroaryl being substituted, also includes the ring and the loop systems that wherein connect the key replacement of the connected carbon atom of key of hydrogen atom.Cycloalkyl, aryl, heterocyclic radical and the heteroaryl being substituted also can by defined below that be substituted or that be unsubstituted alkyl, thiazolinyl and alkynyl substituted.
Alkyl includes the straight or branched group comprising 1 to 20 carbon atom, it is preferable that containing the alkyl of 1 to 12 carbon atom.nullLimiting examples includes methyl、Ethyl、N-pro-pyl、Isopropyl、Normal-butyl、Isobutyl group、The tert-butyl group、Sec-butyl、N-pentyl、1,1-dimethyl propyl、1,2-dimethyl propyl、2,2-dimethyl propyl、1-ethyl propyl、2-methyl butyl、3-methyl butyl、N-hexyl、1-Ethyl-2-Methyl propyl group、1,1,2-thmethylpropyl、1,1-dimethylbutyl、1,2-dimethylbutyl、2,2-dimethylbutyl、1,3-dimethylbutyl、2-ethyl-butyl、2-methyl amyl、3-methyl amyl、4-methyl amyl、2,3-dimethylbutyl、N-heptyl、2-methylhexyl、3-methylhexyl、4-methylhexyl、5-methylhexyl、2,3-dimethyl amyl group、2,4-dimethyl amyl group、2,2-dimethyl amyl group、3,3-dimethyl amyl group、2-ethyl pentyl group、3-ethyl pentyl group、N-octyl、2,3-dimethylhexanyl、2,4-dimethylhexanyl、2,5-dimethylhexanyl、2,2-dimethylhexanyl、3,3-dimethylhexanyl、4,4-dimethylhexanyl、2-ethylhexyl、3-ethylhexyl、4-ethylhexyl、2-methyl-2-ethyl pentyl group、2-methyl-3-ethyl pentyl group、N-nonyl、2-methyl-2-ethylhexyl、2-methyl-3-ethylhexyl、2,2-diethyl amyl group、Positive decyl、3,3-diethylhexyl、2,2-diethylhexyl,And various branched chain isomers etc..More preferably contain the low alkyl group of 1 to 6 carbon atom, non-limiting example includes methyl, ethyl, n-pro-pyl, isopropyl, normal-butyl, isobutyl group, the tert-butyl group, sec-butyl, n-pentyl, 1, 1-dimethyl propyl, 1, 2-dimethyl propyl, 2, 2-dimethyl propyl, 1-ethyl propyl, 2-methyl butyl, 3-methyl butyl, n-hexyl, 1-Ethyl-2-Methyl propyl group, 1, 1, 2-thmethylpropyl, 1, 1-dimethylbutyl, 1, 2-dimethylbutyl, 2, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethyl-butyl, 2-methyl amyl, 3-methyl amyl, 4-methyl amyl, 2, 3-dimethylbutyl etc..Alkyl can be replace or non-substituted, when substituted, substituent group can be replaced on any spendable junction point, described substituent group is preferably one or more following group, and it is independently selected from alkyl, thiazolinyl, alkynyl, alkoxyl, alkylthio group, alkyl amino, halogen, mercaptan, hydroxyl, nitro, cyano group, cycloalkyl, Heterocyclylalkyl, aryl, heteroaryl, cycloalkyloxy, heterocyclylalkoxy groups, cycloalkylthio, heterocycle alkylthio group, oxo ,-C (O) R ' ,-C (O) OR ' ,-S (O)mR′、-NR′R″、-C(O)NR′R″、-NR′C(O)R″、-NR′S(O)mR " or-S (O)mNR′R″。
Cycloalkyl-alkyl refers to the alkyl that the unsaturated monocycle of saturated or part or multi-ring cyclic hydrocarbon replace, and cycloalkyl ring comprises 3 to 20 carbon atoms, it is preferable that comprise 3 to 12 carbon atoms, more preferably comprises 3 to 10 carbon atoms.The limiting examples of monocyclic cycloalkyl includes cyclopropyl, cyclobutyl, cyclopenta, cyclopentenyl, cyclohexyl, cyclohexenyl group, cyclohexadienyl, suberyl, cycloheptatriene base, ring octyl group etc.;Polycyclic naphthene base includes the cycloalkyl of volution, condensed ring and bridged ring.
Thiazolinyl refers to by the unsaturated alkyl as defined above being at least made up of two carbon atoms and at least one carbon-to-carbon double bond, for instance vinyl, 1-acrylic, 2-acrylic, 1-, 2-or 3-cyclobutenyl etc..Thiazolinyl can be replace or non-substituted, when substituted, substituent group is preferably one or more following group, and it is independently selected from alkyl, thiazolinyl, alkynyl, alkoxyl, alkylthio group, alkyl amino, halogen, mercaptan, hydroxyl, nitro, cyano group, cycloalkyl, Heterocyclylalkyl, aryl, heteroaryl, cycloalkyloxy, heterocyclylalkoxy groups, cycloalkylthio, heterocycle alkylthio group ,-C (O) R ' ,-C (O) OR ' ,-S (O)mR′、-NR′R″、-C(O)NR′R″、-NR′C(O)R″、-NR′S(O)mR " or-S (O)mNR′R″。
Cycloalkenyl group refers to include having at least one double bond being between two carbon atoms, unsaturated cycloalkyl as defined above.In some embodiments, cycloalkenyl group can have one, two or three double bonds but not including that aromatic compound.Cycloalkenyl group comprises 4 to 14 carbon atoms, or in some embodiments, comprises 5 to 14 carbon atoms, it is preferable that comprise 5 to 10 carbon atoms, more preferably comprises 5,6,7 or 8 carbon atoms.The example of cycloalkenyl group includes cyclohexenyl group, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl and hexadienyl.
Alkynyl refers to the unsaturated alkyl as defined above being at least made up of two carbon atoms and at least one carbon-to-carbon triple bond, for instance acetenyl, 1-propinyl, 2-propynyl, 1-, 2-or 3-butynyl etc..Alkynyl can be replace or non-substituted, when substituted, substituent group is preferably one or more following group, and it is independently selected from alkyl, thiazolinyl, alkynyl, alkoxyl, alkylthio group, alkyl amino, halogen, mercaptan, hydroxyl, nitro, cyano group, cycloalkyl, Heterocyclylalkyl, aryl, heteroaryl, cycloalkyloxy, heterocyclylalkoxy groups, cycloalkylthio, heterocycle alkylthio group ,-C (O) R ' ,-C (O) OR ' ,-S (O)mR′、-NR′R″、-C(O)NR′R″、-NR′C(O)R″、-NR′S(O)mR " or-S (O)mNR′R″。
Aryl is free from heteroatomic cyclic aromatic hydrocarbon.Aryl includes monocycle, bicyclo-and three-loop system in this article.Therefore, aryl includes but not limited to phenyl, azulene cyclopentacycloheptene base, diphenyl, fluorenyl, phenanthryl, anthryl, indenyl, indanyl, pentalene base and naphthyl.In some embodiments, aryl contains 6-14 carbon in the part of the ring of group, it is preferable that 6 to 12, more preferably 6-10 carbon atom.In some embodiments, aryl is phenyl or naphthyl.Although phrase " aryl " includes the group (such as indanyl, tetralyl etc.) containing the ring (the aromatic-aliphatic loop systems such as condensed) condensed, but its aryl not including there is other group (such as alkyl or halo group) being bonded with one of ring members.The groups such as tolyl are referred to as the aryl being substituted.The representational aryl being substituted can through mono-substituted or be replaced and exceed once.Such as, including but not limited to, through mono-substituted aryl, the phenyl or naphthyl that 2-, 3-, 4-, 5-or 6-replace, it can be replaced by such as substituent group listed above.
The alkyl that aralkyl is as defined above, wherein, the hydrogen of alkyl or carbon bond are connected the key of aryl defined above and are replaced.In some embodiments, aralkyl contains 7 to 16 carbon atoms, it is preferable that 7 to 14 carbon atoms, more preferably 7 to 10 carbon atoms.The aralkyl being substituted can be replaced in the part of alkyl, aryl, or is all replaced at alkyl and aryl moiety.Representational aralkyl includes but not limited to benzyl and phenethyl and (cycloalkylaryl) alkyl (such as 4-indanyl ethyl) condensed.The representational aralkyl being substituted can be replaced once or for several times by such as substituent group listed above.
Heterocyclic radical includes the aromatic series (being also referred to as heteroaryl) containing 3 or multiple ring members and non-aromatic cyclic compound, and one or more in its ring members are hetero atoms, for instance but it is not limited to N, O and S.In some embodiments, heterocyclic radical contains 1,2,3 or 4 hetero atoms.In some instances, heterocyclic radical include having 3 to 16 ring memberses single, two and three rings.Heterocyclic radical includes loop systems aromatic, that part is unsaturated and saturated, for instance, imidazole radicals, imidazolinyl and imidazolidinyl.Phrase " heterocyclic radical " includes the ring species class condensed, these those including comprising the aromatic series condensed and non-aromatic group, for instance benzotriazole base, 2,3-dihydrobenzos [Isosorbide-5-Nitrae] dialkyl group and benzo [1,3] dioxa cyclopentenyl.This phrase also include bridging containing heteroatomic multi-loop system, for instance but be not limited to quininuclidinyl.But, this phrase does not include the heterocyclic radical with other group (such as alkyl, oxo or halo group) being bonded with one of ring members.On the contrary, these are referred to as " heterocyclic radical being substituted ".nullHeterocyclic radical includes but not limited to aziridinyl、Azetidine base、Pyrrolidinyl、Imidazolidinyl、Pyrazolidinyl、Thiazolidinyl、Tetrahydrochysene thio-phenyl、Tetrahydrofuran base、Dioxa cyclopentenyl、Furyl、Thio-phenyl、Pyrrole radicals、Pyrrolinyl、Imidazole radicals、Imidazolinyl、Pyrazolyl、Pyrazolinyl、Triazolyl、Tetrazole radical、Azoles base、Isoxazole base、Thiazolyl、Thiazolinyl、Isothiazolyl、Thiadiazole base、Di azoly、Piperidyl、Piperazinyl、Morpholinyl、Thio-morpholinyl、THP trtrahydropyranyl、Tetrahydrochysene thiopyranyl、Thioxane、Dioxane base、Dithiane base、Pyranose、Pyridine radicals、Pyrimidine radicals、Pyridazinyl、Pyrazinyl、Triazine radical、Dihydropyridine base、Dihydro two thienyl、Dihydro dithione base、Homopiperazine base、Quininuclidinyl、Indyl、Indoline base、Isoindolyl、Azaindolyl (pyrrolopyridinyl)、Indazolyl、Indolizinyl、Benzotriazole base、Benzimidazolyl、Benzofuranyl、Benzo thio-phenyl、Benzothiazolyl、Benzodiazole base、Benzimidazole dihydrochloride base、Benzo two thienyl、Benzo thienyl、Benzothiazine base、Benzoxazolyl group、Benzothiazolyl、Benzothiadiazole base、Benzo [1,3] dioxa cyclopentenyl、Pyrazolopyridine base、Imidazopyridyl (azabenzimidazoles base)、Triazolopyridine base、Isoxazole pyridine radicals、Purine radicals、Xanthinyl、Adenyl、Guanyl-、Quinolyl、Isoquinolyl、Quinolizinyl、Quinoxalinyl、Quinazolyl、Phthalazinyl、Naphthyridinyl、Thianaphthenyl、Dihydrobenzo thiazinyl、Dihydro benzo furyl、Indolinyl、Dihydrobenzo dialkyl group、Tetrahydro indole base、Tetrahydrochysene indazole base、Four benzimidazolyls、Tetrahydro benzo triazolyl、Nafoxidine pyridine radicals、Tetrahydro-pyrazole pyridine radicals、Imidazolidine pyridine radicals、Tetrahydrochysene Triazolopyridine base and tetrahydric quinoline group.The representational heterocyclic radical being substituted can through monosubstituted or be replaced and exceed once, for instance but it is not limited to that 2-, 3-, 4-, 5-or 6-replace or by such as multiple substituent group Disubstituted pyridine base listed above or morpholinyl.
Heteroaryl is the aromatic ring compound containing 5 or more ring members atom, and wherein one or more ring memberses are hetero atoms, for instance but it is not limited to N, O and S.Heteroaryl includes but not limited to following radicals, such as, pyrrole radicals, pyrazolyl, triazolyl, tetrazole radical, azoles base, isoxazole base, thiazolyl, pyridine radicals, pyridazinyl, pyrimidine radicals, pyrazinyl, thio-phenyl, benzo thio-phenyl, furyl, benzofuranyl, indyl, azaindolyl (pyrrolopyridinyl), indazolyl, benzimidazolyl, imidazopyridyl (azabenzimidazoles base), Pyrazolopyridine base, Triazolopyridine base, benzotriazole base, benzoxazolyl group, benzothiazolyl, Benzothiadiazole base, imidazopyridyl, isoxazole pyridine radicals, thianaphthenyl, purine radicals, xanthinyl, adenyl, guanyl-, quinolyl, isoquinolyl, tetrahydric quinoline group, quinoxalinyl and quinazolyl.It is all aromatic fused ring compounds that heteroaryl includes all of which ring, for instance indyl, and it also includes only one of which ring is aromatic fused ring compounds, for instance 2,3-indolinyls.Although phrase " heteroaryl " includes the cycle compound condensed, but this phrase does not include the heteroaryl with other group (such as alkyl) being bonded with one of ring members.On the contrary, the heteroaryl with this type of replacement is referred to as " heteroaryl being substituted ".The representational heteroaryl being substituted can be replaced once or for several times by such as multiple substituent group listed above.
The alkyl that cycloheteroalkylalkyl is as defined above, but wherein, the hydrogen of alkyl or carbon bond are connected the key of heterocyclic radical defined above and are replaced.The cycloheteroalkylalkyl being substituted can be replaced in the part of alkyl, heterocyclic radical, or is all replaced at alkyl and heterocyclyl moieties.Representational cycloheteroalkylalkyl includes but not limited to morpholine-4-base-ethyl, furan-2-base-methyl, imidazol-4 yl-methyl, pyridin-3-yl-methyl, oxolane-2-base-ethyl and indole-2-base-propyl group.The representational cycloheteroalkylalkyl being substituted can be replaced once or for several times by such as substituent group listed above.
The alkyl that heteroarylalkyl is as defined above, wherein, the hydrogen of alkyl or carbon bond are connected the key of heteroaryl defined above and are replaced.The heteroarylalkyl being substituted can be replaced in the part of alkyl, heteroaryl, or is all replaced at alkyl and heteroaryl moieties.The representational heteroarylalkyl being substituted can be replaced once or for several times by such as substituent group listed above.
In the compound of the present invention, the group described herein with two or more junction point (i.e. bivalence, trivalent or multivalence) is named by prefix " Asia ".Such as, divalent alkyl is alkylidene, and divalent aryl is arlydene, and divalent heteroaryl radical is heteroarylidene, etc..The group being substituted with the compound of the present invention with single point of attachment does not use " Asia " to name.It is therefoie, for example, chloroethyl is not referred to as chlorethylidene in this article.
Oxo base refers to that the group being wherein connected with oxygen atom is the alkyl being substituted or being unsubstituted, aryl, heteroaryl, cycloalkyl, alkyl acyl, aryl-acyl, heteroaroyl by the substituted radical constituted that is connected with oxygen atom.Above group is connected with oxygen atom and namely may be constructed alkoxyl, aryloxy group, heteroaryloxy, cycloalkyl oxy, alkyl acyloxy, arylacyloxy, heteroaryl acyloxy group, cycloalkyl acyloxy.
Alkoxyl is the substituent group that in hydroxyl (-OH), the key of the carbon atom that the key of connection hydrogen atom is connected alkyl that is defined above that be substituted or that be unsubstituted is replaced.The example of linear alkoxide groups includes but not limited to methoxyl group, ethyoxyl, propoxyl group, butoxy, amoxy, hexyloxy etc..The example of branched alkoxyl includes but not limited to isopropoxy, sec-butoxy, tert-butoxy, isoamoxy, different hexyloxy etc..The example of cycloalkyloxy includes but not limited to cyclopropyl oxygen, cyclobutyl oxygen, cyclopenta oxygen, cyclohexyl oxygen etc..The representational alkoxyl being substituted can be replaced once or for several times by such as substituent group listed above.
Term " alkanoyl " and " alkanoyl oxygen " refer to-C (O)-alkyl and-O-C (O)-alkyl respectively time used herein, each of which contains 2-5 carbon atom.
Term " aryl oxide " and " alkoxy aryl " refer to the substituent group that aryl that is that be substituted or that be unsubstituted is constituted with oxygen atoms bond, the substituent group that aralkyl that is that be substituted or that be unsubstituted is constituted with oxygen atoms bond respectively.Example includes but not limited to phenoxy group, naphthyl oxygen and benzyloxy.The representational aryl oxide being substituted and alkoxy aryl can be replaced once by such as substituent group listed above or for several times.
Term " carboxylic acid " refers to-COOH group time used herein.
Term " carboxylate " refers to-COOR ' group time used herein.R ' be as defined herein be substituted or the alkyl, cycloalkyl, thiazolinyl, alkynyl, aryl, aralkyl, cycloheteroalkylalkyl or the heterocyclic radical that are unsubstituted.
Term " amide " (or " amide groups ") includes C-amide group and N-amide group, is namely-C (O) NR ' R " and-NR ' C (O) R " group respectively.R ' and R " be independently hydrogen as defined herein or be substituted or the alkyl, thiazolinyl, alkynyl, cycloalkyl, aryl, aralkyl, cycloheteroalkylalkyl or the heterocyclic radical that are unsubstituted.Therefore amide groups includes but not limited to carbamoyl (-C (O) NH2) and carbonylamino group (-NHC (O) H).In some embodiments, amide is-NR ' C (O)-(C1-5Alkyl), this group is referred to as " carbonylamino ", and in other embodiments, amide is-NHC (O)-alkyl, and this group is referred to as " alkanoylamino ".
Term " nitrile " or " cyano group " refer to-CN group time used herein.
Carbaminate/ester includes N-carbamate groups and O-carbamate groups, is namely-NR ' C (O) OR " and-OC (O) NR ' R " group respectively.R ' and R " be independently as defined herein be substituted or the alkyl, thiazolinyl, alkynyl, cycloalkyl, aryl, aralkyl, cycloheteroalkylalkyl or the heterocyclic radical that are unsubstituted.R ' can also is that H.
Term " amine " (or " amino ") refer to-NR ' R time used herein " group, wherein R ' and R " be independently hydrogen as defined herein or be substituted or the alkyl, thiazolinyl, alkynyl, cycloalkyl, aryl, aralkyl, cycloheteroalkylalkyl or the heterocyclic radical that are unsubstituted.In some embodiments, amine is alkyl amino, dialkyl amido, arylamino or alkyl aryl amino.In some other embodiment, amine is NH2, methylamino, dimethylamino, ethylamino, diethylamino, propylcarbamic, isopropylamino, phenyl amino or benzylamino.
Term " sulfonamide " includes S-sulfuryl amine group and N-sulfuryl amine group, is namely-SO respectively2NR ' R " and-NR ' SO2R " group.R ' and R " be independently hydrogen as defined herein or be substituted or the alkyl, thiazolinyl, alkynyl, cycloalkyl, aryl, aralkyl, cycloheteroalkylalkyl or the heterocyclic radical that are unsubstituted.Therefore sulfuryl amine group includes but not limited to sulfonyl (-SO2NH2).In some embodiments herein, sulfonamide is-NHSO2-alkyl, it is referred to as " alkyl sulfonyl-amino ".
Term " mercaptan " refers to-SH group, and sulfide includes-SR ' group, and sulfoxide includes-S (O) R ' group, and sulfone includes-SO2R ' group, and sulfonyloxy includes-OSO2R ', sulphur acyloxy includes-OSO2OR′.R ' be independently as defined herein be substituted or the alkyl, cycloalkyl, thiazolinyl, alkynyl, aralkyl base, heterocyclic radical or the cycloheteroalkylalkyl that are unsubstituted.In some embodiments, sulfide is alkylthiol groups ,-S-alkyl.
Term " urea " refers to-NR '-C (O)-NR ' R " group.R ' and R " group be independently hydrogen as defined herein or be substituted or the alkyl, thiazolinyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclic radical or the cycloheteroalkylalkyl that are unsubstituted.
Term " amidine " refers to-C (NR ') NR ' R " and-NR ' C (NR ') R ", wherein, R ' and R " each be independently hydrogen as defined herein or be substituted or the alkyl, cycloalkyl, thiazolinyl, alkynyl, aralkyl base, heterocyclic radical or the cycloheteroalkylalkyl that are unsubstituted.
Term " guanidine " refers to-NR ' C (NR ') NR ' R ", wherein R ' and R " each be independently hydrogen as defined herein or be substituted or the alkyl, cycloalkyl, thiazolinyl, alkynyl, aralkyl base, heterocyclic radical or the cycloheteroalkylalkyl that are unsubstituted.
Term " enamine " refers to-C (R ')=C (R ') NR ' R " and-NR ' C (R ')=C (R ') R ", wherein R ' and R " each be hydrogen as defined herein independently, be substituted or the alkyl, cycloalkyl, thiazolinyl, alkynyl, aralkyl base, heterocyclic radical or the cycloheteroalkylalkyl that are unsubstituted.
Term " halogen " or " halo " refer to bromine, chlorine, fluorine or iodine time used herein.In some embodiments, halogen is fluorine.In some other embodiment, halogen is chlorine or bromine.
Term " hydroxyl " can refer to-OH or its ionized form-O time used herein-。
Term " acid imide " refers to-C (O) NR ' C (O) R ", wherein R ' and R " each be independently hydrogen as defined herein or be substituted or the alkyl, cycloalkyl, thiazolinyl, alkynyl, aralkyl base, heterocyclic radical or the cycloheteroalkylalkyl that are unsubstituted.
Term " nitrogen heterocycle " refers to the ring system containing nitrogen-atoms, this ring system can " a pair of horses going side by side close " fragrant and non-aromatic ring system, or pass through " spiral shell carbon atom " and link other ring systems, for instance following structure:
Etc..
Term " imines " refers to-CR ' (NR ") and-N (CR ' R ") group, wherein R ' and R " each be independently hydrogen as defined herein or be substituted or the alkyl, cycloalkyl, thiazolinyl, alkynyl, aralkyl base, heterocyclic radical or the cycloheteroalkylalkyl that are unsubstituted and meet: R ' and R " different time be hydrogen.
Term " nitro " refers to-NO time used herein2。
Term " trifluoromethyl " refers to-CF time used herein3。
Term " trifluoromethoxy " refers to-OCF time used herein3。
The officinal salt of compound described herein is within the scope of the invention, it includes such acid-addition salts or base addition salts, described salt maintains intended pharmacological activity and is not have potential ill effect (such as salt does not have undue toxicity, sensitization or zest, and is bioavailable) from angle biology.When the compound of the present invention has basic group (such as, amino) time, officinal salt can be formed with mineral acid (such as hydrochloric acid, hydrogen borate, nitric acid, sulphuric acid and phosphoric acid), organic acid (such as alginate, formic acid, acetic acid, benzoic acid, gluconic acid, Fumaric acid, oxalic acid, tartaric acid, lactic acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, LOMAR PWA EINECS 246-676-2 and p-methyl benzenesulfonic acid) or acidic amino acid (such as aspartic acid and glutamic acid).When the compound of the present invention has acidic-group, for instance during hydroxy-acid group, it can with metal, for instance alkali and alkaline earth metal ions (such as Na+、Li+、K+、Ca2+、Mg2+、Zn2+), ammonia or organic amine (such as dicyclohexylamine, Trimethylamine, triethylamine, pyridine, ethanolamine, diethanolamine, triethanolamine) or basic amino acid (such as arginine, lysine and ornithine) form salt.This type of salt " one kettle way " can be prepared during to the separation of compound and purification, or can prepare this type of salt by individually being reacted with suitable acid or alkali respectively and separate the salt being consequently formed by purified to free alkali or free acid rear compound.
Well known by persons skilled in the art, the compound of the present invention can show tautomerism, conformational isomerism, geometrical isomerism and/or stereomeric phenomenon.Although the formula figure in specification and claims only represents one of possible tautomerism, conformational isomerism, stereoisomerism or geometrical isomerism form, it is understood that the present invention include compound there is any tautomerism of one or more purposes described herein, conformational isomerism, stereoisomerism and/or geometrical isomerism form and these multiple multi-form mixture.
Those skilled in the art are understandable, and large-scale functional group and other structure can show tautomer, and all tautomers of compound described herein are within.
Spatial chemistry unless specifically indicated, the stereoisomer of compound, including all chiralitys of structure, diastereo-isomerism and racemic form.Therefore, the optical isomer in the enrichment of any or all asymmetric atom place or fractionation is included for the compound in the present invention.Raceme and diastereomeric mixtures, and each optical isomer, all can separated or synthesis, to be substantially free of its corresponding isomer or diastereomer, these stereoisomers are also within the scope of the invention.
The compound of the present invention can exist as solvate, especially as hydrate.Hydrate can be formed during the manufacture of compound or the compositions of inclusion compound, or hydrate can be formed due to the hygroscopic nature of compound over time.The compound of the present invention is alternatively arranged as organic solvate to be existed, including ether and solvate etc..Qualification and preparation to any specific solvate are all that synthesis is organic or medicinal chemistry art those of ordinary skill is known.
Lipid includes that synthesize and naturally occurring fat-soluble compound, and it includes neutrality and amphiphatic molecule.Both sexes lipid typically comprises hydrophilic component and hydrophobic components.Exemplary lipid includes fatty acid, triglyceride, neutral fat, phospholipid, candy fat, fatty alcohol, wax, terpene, steroid (such as cholesterol) and surfactant.
" lipid reduction reagent " has the compound of one or more following effects when referring to be administered to patient time used herein: the liver increasing LDLR is expressed;Increase the LDLRmRNA half-life in hepatocyte;Increase the liver picked-up to blood plasma LDL, cholesterol or triglyceride;Strengthen the fatty acid oxidation of liver, reduce triglyceride synthesis and the secretion of liver, and reduce blood plasma and/or the T-CHOL of liver, LDL-cholesterol, VLDL-cholesterol or triglyceride levels.Lipid disclosed herein reduces reagent and includes the compound in the present invention.
In one aspect, the invention provides the purposes utilizing the compounds of this invention manufacture in reducing the medicine of lipid levels of patients blood plasma and/or liver, reduce compound as described herein or the compositions of effective dose including using lipid to described patient.The lipid levels reduced can be one or more in T-CHOL, LDL-cholesterol (LDL-C), triglyceride (TG) and nonesterified long-chain fatty acid.
Compound described herein and compositions can be used for preventing or treat following disease, including such as, and hyperlipemia, hypercholesterolemia, hypertriglyceridemia, fatty liver (fatty degeneration of liver), type ii diabetes, hyperglycemia, obesity or insulin resistance and metabolism syndrome.The method for the treatment of includes compound as herein described or the compositions of the experimenter's administering therapeutic effective dose to needs treatment.The compound of the present invention can be additionally used in treatment or prevention is characterised by the blood plasma that raises or liver cholesterol or triglyceride or the morbid state relevant to the blood plasma raised or liver cholesterol or triglyceride or morbid state.The technology of the present invention also provides for using the compounds of this invention manufacture treatment or prevention disease (such as, hyperlipemia, hypercholesterolemia, hypertriglyceridemia, fatty liver, type ii diabetes, hyperglycemia, obesity or insulin resistance or metabolism syndrome) the purposes of effective dose medicine.
Compound disclosed herein and compositions are expressed by increasing the liver of LDLR, by increasing the stability of LDLRmRNA, by increasing LDLR genetic transcription, by suppressing the degraded of the LDLR albumen that mediates of proprotein convertase subtilisin/kexin9 type (proproteinconvertasesubtilisin/kexintype9) (PCSK9) or the whole of above-mentioned possible cell mechanism, reduce lipid levels.The LDLR level increased in liver adds picked-up and the processing of blood plasma LDL-C, thus causing that the blood plasma level of cholesterol, LDL-C and triglyceride reduces.Additionally, compound can pass through to activate the AMP protein kinase (AMPK) (key molecule of bio-energy Metabolism regulation) activated increases the phosphorylation of acetyl CoA carboxylase (ACC).The phosphorylation of the increase of ACC enhances the fatty acid oxidation in liver, the TG accumulation causing liver reduces, and cause that TG secretes with VLDL form, this additionally aids the blood plasma level reducing TG, LDL-C, T-CHOL and nonesterified long-chain fatty acid, thus preventing or treating the disease relevant to hyperlipemia.On the other hand, it is believed that, hereditism and pharmaceutical research show, AMPK is that body keeps necessary to glucose balance, and compound, by activating AMPK, finally plays treatment type ii diabetes, hyperglycemia, obesity or insulin resistance or metabolism syndrome.
In yet another aspect, compound provided by the invention has increases the LDLR purposes expressed, and including to needing its compound as herein described of experimenter's administering therapeutic effective dose or compositions, thus increases the LDLR in described experimenter and expresses.In another aspect of this invention, the invention provides a kind of purposes utilizing the compounds of this invention to reduce plasma LDL-cholesterol and/or plasma triglyceride, including to needing its compound as herein described of patient therapeuticallv's effective dose or compositions, thus reduce the plasma LDL-cholesterol of described patient.
In yet another aspect, the invention provides the lipid including compound and compositions thereof and reduce reagent.Compound and compositions can be used in method and the treatment of reduction lipid as herein described.In one embodiment, the invention provides Formula V compound, its stereoisomer, its tautomer, its solvate and/or its officinal salt.
In yet another aspect, present technology provides the pharmaceutical composition comprising any compound disclosed herein and pharmaceutically suitable carrier or one or more excipient or filler and medicament.In some embodiments, it is provided that the pharmaceutical composition of the patient's condition of the group of free hyperlipemia, hypercholesterolemia, hypertriglyceridemia, fatty degeneration of liver and metabolism syndrome composition is selected in treatment.Such composition includes lipid and reduces as herein described any compound of effective dose.In one embodiment, pharmaceutical composition is packaged into unit dosage form.When being administered to the experimenter needing it, unit dosage form can effectively reduce the lipid levels (at least one in such as T-CHOL, LDL-cholesterol, triglyceride and nonesterified long-chain fatty acid) in blood flow and/or liver.
Can pass through to mix one or more compounds of the present invention, its officinal salt, its stereoisomer, its tautomer or its solvate with pharmaceutically suitable carrier, excipient, binding agent, diluent etc., prepare pharmaceutical composition, to prevent or to treat the disease relevant to the lipid levels of the blood plasma increased and/or liver.Compound as herein described can be used for preparing formulation and the medicament of the blood plasma preventing or treating and increase and/or the relevant various disease conditions (such as hyperlipemia, hypercholesterolemia, fatty degeneration of liver and metabolism syndrome) of liver lipid levels with compositions.Such composition can be the form of such as granule, powder, tablet, capsule, syrup, suppository, injection, emulsion, elixir, suspension or solution.The compositions of the present invention can be formulated for the various forms of multiple route of administration, for instance, by oral, parenteral, locally, rectum, per nasal, vaginal application or used by the storage implanted.Parenteral or systemic administration include but not limited to subcutaneous, intravenous, intraperitoneal and intramuscular, injection.Following dosage form provides as an example, and it is not necessarily to be construed as the technology of the restriction present invention.
Pharmaceutical composition containing active component can apply to the form being administered orally, for instance tablet, dragee, lozenge, water or oil suspension, dispersibles powder or granule, emulsion, hard or soft capsule, or syrup or elixir.Can preparing Orally administered composition according to any known method preparing Pharmaceutical composition in this area, such composition can contain one or more selected from following composition: sweeting agent, correctives, coloring agent and preservative, to provide pleasing and good to eat pharmaceutical formulation.Tablet contains active component and the suitable nontoxic pharmaceutically useful excipient preparing tablet for mixing.These excipient can be inert excipient, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate;Granulating agent and disintegrating agent, for instance microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, corn starch or alginic acid;Binding agent, for instance starch, gelatin, polyvinylpyrrolidone or arabic gum and lubricant, for instance magnesium stearate, stearic acid or Pulvis Talci.These tablets can not maybe can pass through cover the taste of medicine or postpone disintegrate and absorption in the gastrointestinal tract by coating, thus provides the known technology of slow releasing function by its coating in a long time.Such as, water soluble taste can be used to shelter material, for instance hydroxypropyl methyl cellulose or hydroxypropyl cellulose, or extend time material such as ethyl cellulose, acetylbutyrylcellulose.
Also can use wherein active component and the inert solid diluent hard gelatin capsule that such as calcium carbonate, calcium phosphate or Kaolin mix, or wherein active component provides oral formulations with water-solubility carrier such as Polyethylene Glycol or oil soluble matchmaker such as Oleum Arachidis hypogaeae semen, liquid paraffin or mixed with olive oil Perle.
Water slurry contains active substance and the suitable excipient preparing water slurry for mixing.This type of excipient is suspending agent, for instance sodium carboxy methyl cellulose, methylcellulose, hydroxypropyl methyl cellulose, sodium alginate, polyvinylpyrrolidone and arabic gum;Dispersant or wetting agent can be naturally-produced phospholipid such as lecithin, or the condensation product of alkylene oxide and fatty acid such as Myrj 45, or the condensation product of oxirane and long-chain fatty alcohol, such as 17 carbon ethyleneoxy group spermol, or oxirane and the condensation product by the derivative part ester of fatty acid and hexitol, such as polyoxyethylene sorbitol monoleate, or oxirane and the condensation product by the derivative partial ester of fatty acid and hexitan, for instance poly(ethylene oxide) Arlacel-80.Aqueous suspension can also contain one or more preservative such as ethyl hydroxybenzoate or nipalgin n-propyl, one or more coloring agent, one or more tender taste agent and one or more sweeting agents, for instance sucrose, saccharin or aspartame.
Oil suspension can pass through to make active component be suspended in vegetable oil such as Oleum Arachidis hypogaeae semen, olive oil, Oleum sesami or Oleum Cocois, or formulated in mineral oil such as liquid paraffin.Oil suspension can contain thickening agent, for instance Cera Flava, hard paraffin or spermol.Above-mentioned sweeting agent and tender taste agent can be added, to provide good to eat preparation.These compositionss can be preserved by addition antioxidant such as butylated hydroxyanisole or alpha-tocopherol.
Can make to be applicable to prepare water suspendible dispersible powder and granule also provide active component and for the dispersant mixed or wetting agent, suspending agent or one or more preservative by adding water.Suitable dispersant or wetting agent and suspending agent can illustrate above-mentioned example.Also other excipients such as sweeting agent, tender taste agent and coloring agent can be added.These compositionss are preserved by adding antioxidant such as ascorbic acid.
The pharmaceutical composition of the present invention can also be the form of oil in water emulsion.Oil phase can be vegetable oil such as olive oil or Oleum Arachidis hypogaeae semen, or mineral oil such as liquid paraffin or its mixture.Suitable emulsifying agent can be naturally-produced phospholipid, for instance soybean lecithin and by the derivative ester of fatty acid and hexitan or partial ester such as sorbitan monooleate, and the condensation product of described partial ester and oxirane, for instance polyoxyethylene sorbitol monoleate.Emulsion can also contain sweeting agent, tender taste agent, preservative and antioxidant.Available Sweetening agents such as glycerol, propylene glycol, sorbitol or sucrose syrup blend and elixir.This type of preparation also can contain demulcent, preservative, coloring agent and antioxidant.
Pharmaceutical composition can be sterile injectable aqueous form.Water, ringer's solution and isotonic sodium chlorrde solution can be had in the acceptable solvent used and solvent.Aseptic injection preparation can be that wherein active component is dissolved in the aseptic injection oil-in-water microemulsion of oil phase.Such as active component is dissolved in the mixture of soybean oil and lecithin.Then oil solution is added process in the mixture of water and glycerol and forms microemulsion.The a large amount of injection in local can be passed through, injection or microemulsion are injected in the blood flow of patient.Or, it is desirable to solution and microemulsion is given by the mode that can keep the compounds of this invention constant circulating concentration.For keeping this constant density, continuous intravenous delivery device can be used.
Pharmaceutical composition could be for the aseptic injection water of intramuscular and subcutaneous administration or the form of oil suspension.Can by known technology, the dispersant suitable by those described above or wetting agent and suspending agent prepare this suspension.Aseptic injection preparation can also be aseptic injectable solution or the suspension of preparation in the acceptable diluent of nontoxic parenteral or solvent, for instance the solution of preparation in 1,3 butylene glycol.In addition, it is convenient to aseptic fixing oil as solvent or suspension media.For this purpose it is proposed, the fixing oil of any mediation including synthetic glycerine list or diester can be used.Additionally, fatty acid such as oleic acid can also prepare injection.
Dosage form for local (including buccal and Sublingual) or the compound of the transdermal administration present invention includes powder, spraying, ointment, paste, emulsifiable paste, washing liquid, gel, solution and paster.Active component can aseptically with pharmaceutically suitable carrier or excipient and be likely to any preservative of needing or buffer agent mixes.Powder and spraying can such as be prepared with excipient (such as the mixture of sugar, Muscovitum, silicic acid, sodium hydroxide, calcium silicates and polyamine powder or these materials).Ointment, paste, emulsifiable paste and gel also can contain following excipient, for instance, animal and plant fat, oil, wax, paraffin, starch, tragacanth, cellulose derivative, Polyethylene Glycol, silicone, bentonite, silicic acid, Muscovitum and zinc oxide or its mixture.It is also possible to use absorption enhancer, the compound increasing the present invention penetrates the flowing of skin.By providing rate controlling membranes (such as a part for percutaneous plaster) or compound can be scattered in the speed controlling this type of flowing in polymeric matrix or gel.
The compounds of this invention can be given by the suppository form for rectally.Can pass through by medicine be solid at normal temperatures but in the rectum for liquid, thus can dissolve in the rectum and discharge the suitable nonirritant excipient of medicine and mix and prepare these pharmaceutical compositions.This type of material includes the mixture of the fatty acid ester of cocoa butter, glycerin gelatine, hydrogenated vegetable oil, the Polyethylene Glycol of various molecular weight and Polyethylene Glycol.
The compound of the present invention also can be used together with can be used for treating or prevent other traditional treatment agent of hyperlipemia disease.For including but not limited to that anti-inflammatory medicine, therapeutic antibodies and cholesterol reduce medicine with the exemplary treatment reagent of the combination treatment of one or more compounds of the present invention, for instance, statin.Can be used for the useful additional treatment reagent of formulated in combination thing and cooperation treatment to include, for instance, anti-hyperlipidemia reagent;Antilipemic exception reagent;Anti-diabetic reagent, includes but not limited to cholesteral biosynthesis inhibitor, for instance HMG-CoA reductase inhibitor (is also referred to as statin, lovastatin, simvastatin, pravastatin, fluvastatin, Rosuvastatin, Pitavastatin and atorvastatin);HMG-CoA reduces synthase inhibitor;Squalene epoxidase inhibitor or inhibitor for squalene synthetic enzyme (being also known as squalene synthase inhibitor);Microsomal triglyceride transfer protein (MTP) inhibitor;Cholic acid chelating agent anion exchange resin, includes but not limited to cholestyramine, cholestipol, the dialkylaminoalkyl derivative of colesevelam or crosslinked glucosan;Ldl receptor derivant;Fibrates, includes but not limited to clofibrate, bezafibrate, fenofibrate and gemfibrozil;Metformin, rosiglitazone, blood plasma HDL-elevating agent, include but not limited to nicotinic acid, fibrates;Anti-hypercholesterolemiccompounds reagent, includes but not limited to cholesterol-uptake inhibitor;Acyl-coenzyme a cholesterol acyltransferase (ACAT) inhibitor, includes but not limited to that amine of Merrill Lynch;Probucol;Nicotinic acid and salt thereof;Nicotiamide;Cholesterol absorption inhibitor, includes but not limited to cupreol or ezetimibe;Vitamin B6 (pyridoxol) and officinal salt thereof, for instance HCl salt;Vitamin B12(cobalamin);Vitamin B3(nicotinic acid and nicotiamide);Antioxidant vitamin, includes but not limited to vitamin C and vitamin E and bata-carotene;Beta receptor blockers;Angiotensin-ii receptor (AT1) antagonist;Angiotensin-convertion enzyme inhibitor, renin inhibitor;Anticoagulant, includes but not limited to fibrinogen deceptor antagonists, i.e. glycoprotein iib/iiia fibrinogen deceptor antagonists;Hormone, includes but not limited to estrogen;Insulin;Ion exchange resin;Ω-3 oil;Benfluorex;26 carbon 5 alkene acid ethyl ester and amlodipine.Adjunctive therapy may also include increase exercise, operation and change meals (such as becoming low cholesterol diet) some plant medicineses and also can be effectively used for formulated in combination thing and cooperation therapy, to treat hyperlipemia, for instance curcumin, balosam sterone, Bulbus Allii, Semen sojae atricolor, soluble fiber, fish oil, green tea, carnitine, chromium, coenzyme Q10, Semen Vitis viniferae extract, dimerization pantothenic acid, Monas cuspurpureus Went and Lac regis apis.
Berberine and related compound also can treat reagent as second, reduce with the lipid of the present invention together with reagent and use.Such as; berberine sulfate, berberine hydrochloride, berberine chloride, oxygen berberine, dihydroberberine, 8-cyano group dihydroberberine, N-1 N-oxide, N-1, protoberberine, 9-ethoxy carbonyl berberine, 9-N, N-formyl-dimethylamino berberine and 12-bromo berberine, berberine azide and berberine glycine betaine can be used.
Also can modify the compound of the present invention, for instance couple organic structure fragment by covalency or conjugate carries out, to improve pharmacokinetic property, toxicity or bioavailability (Half-life in vivo such as increased).Conjugate can be linear or branched hydrophilic polymer group, fatty acid group or fatty acid ester group.Polymer-based group can comprise the molecular weight that can be regulated by those skilled in the art, to improve, for instance pharmacokinetic property, toxicity or bioavailability.Exemplary conjugate can include poly-alkanol (such as Polyethylene Glycol (PEG), polypropylene glycol (PPG)), carbohydrate polymer, amino acid polymer or polyvinylpyrrolidone and fatty acid or fatty acid ester group, each of which can independently comprise about 8 to about 70 carbon atoms.Conjugate for using together with the compound of the present invention also acts as joint, for instance for any suitable substituent group or group, radioactive label (mark or label), halogen, albumen, enzyme, polypeptide, other treatment reagent (such as medicine or medicine), nucleoside, dyestuff, oligonucleotide, lipid, phospholipid and/or liposome.In one aspect, conjugate can include polyvinylamine (PEI), polyglycine, PEI and the crossbred of polyglycine, Polyethylene Glycol (PEG) or methoxy poly (ethylene glycol) (mPEG).The compound of the present invention also can be connected to by conjugate, for instance, labelling (that fluoresce or luminescence) or mark (radioactivity element, radiosiotope and/or isotope), to comprise the probe of the present invention.The conjugate used together with the compound of the present invention can improve Half-life in vivo in one aspect.
Term " link " and/or " combination " can represent and chemically or physically interact, for instance between compound and the target interested of the present invention.The example linked or interact includes covalent bond, ionic bond, hydrophilic-hydrophobic interacts, hydrophobic-hydrophobic interacts and complex." link " generally also may be referred to " combination " or " affinity ", and each of which is used equally to describe and multiple chemically or physically interacts.Measurement combination or affinity are also the routine techniquess of those skilled in the art.
Provided herein is the following examples to set forth advantages of the present invention, and assist those of ordinary skill in the art's preparation further or use the compound or its salt of the present invention, pharmaceutical composition, derivant, metabolite, prodrug, racemic mixture or tautomeric form.The embodiments herein is additionally operable to set forth preferred aspect of the present invention.Embodiment is not construed in any way as limiting the scope of the present invention defined by the appended claims.
Detailed description of the invention
The conventional method of the present invention explained further below, the compound of the present invention can be prepared by method as known in the art, is described in detail for the preparation method of preferred compounds of the invention below but the preparation method of the compounds of this invention is not limited to this.
General formula compound disclosed by the invention (V) preparation is prepared essentially according to following scheme:
Above syntheti c route describes as follows: X1 and X2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.X1 and X2, under certain reaction condition, obtains compounds X 3 by certain amide method of attachment, and what intermediate X 3 was reacted under the effect of dehydrant obtains X4, in intermediate X 4, carbon-to-nitrogen double bon is after reducing agent effect, nitrogen-atoms occurs coupled reaction to obtain compound V further, wherein A, R1~R15, q, described in t literary composition as defined above.
Further, formula (VII):
Above syntheti c route describes as follows: Y1 and Y2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.Y1 and Y2 is under certain reaction condition, compound Y3 is obtained by amide method of attachment, what intermediate Y3 reacted under the effect of dehydrant obtains Y4, in intermediate Y4, carbon-to-nitrogen double bon is after reducing agent effect, the further coupled reaction of nitrogen-atoms obtains compound Y5, intermediate Y5 occur further point in cyclization be obtained by reacting compound VII, wherein A, R1~R4, R6~R15, q, described in t literary composition as defined above.
Further illustrate the present invention below by specific embodiment, but those skilled in the art are it should be understood that the present invention is not limited in these embodiments.
The structure of compound is determined by nuclear magnetic resonance, NMR (NMR) or mass spectrum (MS).The mensuration of NMR is to use BrukerAVANCE-400 nuclear magnetic resonance spectrometer, and measuring solvent is deuterated dimethyl sulfoxide (DMSO-d6), deuterochloroform (CDCl3), deuterated methanol (CD3OD), being inside designated as tetramethylsilane (TMS), chemical shift is with 10-6(ppm) provide as unit.
The mensuration of MS is with FINNIGANLCQAd (ESI) mass spectrograph (manufacturer: Thremo model: FinniganLCQadvantageMAX)
Tlc silica gel plate uses Yantai Huanghai Sea HSGF254 or Qingdao GF254 silica gel plate, and the specification of the silica gel plate that thin layer chromatography (TLC) uses is 0.15mm~0.2mm, and the specification that thin layer chromatography separation purified product adopts is 0.4mm~0.5mm silica gel plate.
It is carrier that column chromatography generally uses the Yantai Huanghai Sea 200~300 order silica gel.
The known initiation material of the present invention can adopt or synthesize according to methods known in the art, or commercially available from GmbH&Co.KG, AcrosOrgannics, AldrichChemicalCompany, TCIChemicals, pacifies the Xue Deng of resistance to Jilin Chemical company.
In embodiment if no special instructions, reaction all carries out under argon atmospher or blanket of nitrogen.
Argon atmospher or blanket of nitrogen refer to that reaction bulb connects argon ball or the nitrogen ball of an about 1L volume.
Nitrogen atmosphere refers to that reaction bulb connects the hydrogen balloon of an about 1L volume.
The normal evacuation of hydrogenation, is filled with hydrogen, repeatable operation 3 times.
In embodiment if no special instructions, the temperature of reaction is room temperature, and temperature range is 20 DEG C~30 DEG C
The monitoring of the reaction process in embodiment adopts thin layer chromatography (TLC), the system of the developing solvent that reaction uses has: A: dichloromethane and methanol system, B: normal hexane and ethyl acetate system, C: normal hexane and acetone system, D: normal hexane, E: ethyl acetate, the volume ratio of solvent is adjusted according to the polarity difference of compound, it is also possible to add a small amount of triethylamine and acidity or alkaline reagent etc. are adjusted.
The system of the system of the eluant of the column chromatography that purifying compounds adopts and the developing solvent of thin layer chromatography includes: A: dichloromethane and methanol system, B: normal hexane and ethyl acetate system, C: normal hexane and acetone system, D: normal hexane, E: ethyl acetate, the volume ratio of solvent is adjusted according to the polarity difference of compound, it is also possible to add a small amount of triethylamine and acidity or alkaline reagent etc. are adjusted.
Embodiment 1
Adding 1A (508 μ L, 3.01mmol), 1B (500mg, 3.01mmol) in 25mL round-bottomed flask, be placed in oil bath, heating, to 150 DEG C, is melt into liquid, stirring reaction 2.5h.Being cooled to room temperature, add ethyl acetate, milled solids, sucking filtration, ethyl acetate is washed, and obtains off-white color solid 1C (765mg, productivity 77.3%) after draining
50mL round-bottomed flask adds 1C (500mg, 1.52mmol), toluene (3mL), phosphorus oxychloride (750 μ L), stirring reaction 2h in 110 DEG C of oil baths, it is cooled to room temperature, saturated sodium bicarbonate aqueous solution cancellation, extraction into ethyl acetate, water washing is added under ice bath, anhydrous sodium sulfate dries, and is spin-dried for and obtains grease.This grease methanol (15mL) dissolves, stir under room temperature, it is dividedly in some parts sodium borohydride (115mg, 3.04mmol), finishes, 20min is stirred under room temperature, reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, being spin-dried for, the residue obtained is through column chromatography (dichloromethane: methanol 50:1;Petroleum ether: ethyl acetate 1:1) purification obtains compound 1D (433mg, productivity 91.0%).1HNMR(400MHz,CDCl3) δ 7.19 7.13 (m, 2H), 6.89 6.84 (m, 2H), 6.58 (s, 1H), 6.55 (s, 1H), 4.18 (dd, J=8.6,5.1Hz, 1H), 3.85 (s, 3H), 3.80 (s, 3H), 3.78 (s, 3H), 3.23 (dt, J=11.9,5.8Hz, 1H), 3.15 (dd, J=13.7,5.0Hz, 1H), 3.02 2.91 (m, 2H), 2.83 2.70 (m, 2H) .MS (ESI) m/z [M+H]+,314.25。
50mL round-bottomed flask adds 1D (75mg, 0.240mmol), it is dissolved in dichloromethane (10mL), add triethylamine (40 μ L, 0.288mmol), 1E (38 μ L, 0.288mmol), stirring 3h under room temperature, reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, organic facies anhydrous sodium sulfate dries, being spin-dried for, the residue obtained separates purification through preparation TLC (petroleum ether: ethyl acetate 2:1) and obtains compound as white solid 1 (72mg, productivity 63.7%).1HNMR(400MHz,CDCl3null)δ7.44–7.36(m,1H),7.35–7.26(m,2H),7.14(td,J=8.2,2.0Hz,1H),6.98–6.91(m,2H),6.80–6.72(m,2H),6.46(s,1H),6.18(s,1H),5.06(t,J=6.8Hz,1H),3.80(s,3H),3.78(s,3H),3.75–3.68(m,1H),3.66(s,3H),3.48–3.38(m,1H),3.10(dd,J=13.6,6.6Hz,1H),2.99(dd,J=13.6,7.1Hz,1H),2.75–2.63(m,1H),2.49(dt,J=16.3,3.9Hz,1H);MS(ESI)m/z[M+K]+: 510.06.
Embodiment 2
50mL round-bottomed flask adds 2A (100mg, 0.319mmol), it is dissolved in dichloromethane (10mL), add triethylamine (67 μ L, 0.479mmol), 2B (69 μ L, 0.639mmol), stirring 3h under room temperature, reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, organic facies anhydrous sodium sulfate dries, being spin-dried for, the residue obtained separates purification through preparation TLC (petroleum ether: ethyl acetate 2:1) and obtains colourless paste compound 2 (121mg, productivity 90.3%).1HNMR(400MHz,CDCl3) δ 7.07 7.00 (m, 2H), 6.85 6.78 (m, 2H), 6.58 (s, 1H), 6.12 (s, 1H), 4.86 (t, J=6.9Hz, 1H), 3.84 (s, 3H), 3.78 (s, 3H), 3.72 (ddd, J=13.6,6.3,2.2Hz, 1H), 3.62 (s, 3H), 3.38 (ddd, J=13.8,11.4,4.6Hz, 1H), 3.17 (dd, J=13.6,6.4Hz, 1H), 3.06 2.93 (m, 2H), 2.66 2.55 (m, 7H);MS(ESI)m/z[M+H]+: 421.12
Embodiment 3
100mL round-bottomed flask adds 3A (1.5g, 6.97mmol), dissolves with dichloromethane (40mL), add oxalyl chloride (893 μ L, 10.5mmol), DMF (1), stirring reaction 2h under room temperature, reactant liquor is evaporated off solvent, obtains 3B, standby.
100mL round-bottomed flask adds 3C (1.18mL, 6.97mmol), dissolves with dichloromethane (20mL), stir under ice bath, add triethylamine (1.07mL, 7.67mmol), be added dropwise over 3B, drip and finish, react overnight under room temperature.Reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, and is spin-dried for, and the residue obtained separates purification through column chromatography (dichloromethane) and obtains white solid 3D (1.85g, productivity 70.2%).
50mL round-bottomed flask adds 3D (900mg, 2.38mmol), toluene (5mL), phosphorus oxychloride (1.2mL), stirring reaction 2h in 110 DEG C of oil baths, it is cooled to room temperature, saturated sodium bicarbonate aqueous solution cancellation, extraction into ethyl acetate, water washing is added under ice bath, anhydrous sodium sulfate dries, and is spin-dried for and obtains grease.This grease methanol (20mL) dissolves, stir under room temperature, it is dividedly in some parts sodium borohydride (180mg, 4.76mmol), finish, under room temperature, stir 20min, reactant liquor is spin-dried for, residue adds water and extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, and is spin-dried for and obtains compound 3E.It is directly used in next step reaction.
50mL round-bottomed flask adds 3E (250mg, 0.690mmol), it is dissolved in dichloromethane (10mL), add triethylamine (144 μ L, 0.288mmol), 3F (110 μ L, 0.828mmol), stirring 3h under room temperature, reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, organic facies anhydrous sodium sulfate dries, being spin-dried for, the residue obtained separates purification through column chromatography (petroleum ether: ethyl acetate 8:1) and obtains colourless paste 3G (349mg, productivity 97.2%).
25mL round-bottomed flask adds 3G (150mg; 0.288mmol); palladium (3mg; 0.014mmol), 3H (11mg, 0.029mmol); potassium carbonate (80mg; 0.576mmol), DMA (4mL), stirs 10h in 130 DEG C of oil baths under nitrogen protection; it is cooled to room temperature; add water and extraction into ethyl acetate, collect organic facies, water washing; anhydrous sodium sulfate dries; being spin-dried for, the residue obtained separates purification through preparation TLC (petroleum ether: ethyl acetate 5:1) and obtains off-white color solid chemical compound 3 (39mg, productivity 30.8%).1HNMR(400MHz,CDCl3null)δ8.41(d,J=7.8Hz,1H),7.62–7.58(m,1H),7.56–7.51(m,1H),7.44(td,J=8.1,5.4Hz,1H),7.37–7.27(m,3H),7.25–7.18(m,1H),6.54(s,1H),4.60(dd,J=13.6,4.3Hz,1H),4.13(ddd,J=13.9,4.3,2.2Hz,1H),3.85(s,3H),3.64(s,3H),3.36–3.25(m,1H),3.13(dd,J=13.8,4.4Hz,1H),3.03(t,J=13.7Hz,1H),2.55–2.46(m,1H),2.46–2.35(m,1H);MS(ESI)m/z[M+H]+: 440.11.
Embodiment 4
Preparation scheme and pertinent literature with reference to embodiment 3 prepare compound 4, MS (ESI) m/z [M+H]+: 521.33.
Embodiment 5
100mL round-bottomed flask adds sodium hydroxide (4g), dissolves with water (50mL), be cooled to room temperature, add 5A (5.07g, 0.033mol), stirring and dissolving, then it is dividedly in some parts 5B (6.29g, 0.033mol), finish, stirred overnight at room temperature.Reactant liquor aqueous hydrochloric acid solution (2mol/L) regulates pH to 4, precipitates out solid, sucking filtration, water washing, collecting filter cake, filter cake dissolves with sodium hydrate aqueous solution (2mol/L) again, filters insoluble matter, the filtrate obtained regulates pH to 4 with aqueous hydrochloric acid solution (2mol/L), precipitate out solid, sucking filtration, water washing, obtain white solid 5C (5.15g, productivity 50.9%) after drying.
100mL round-bottomed flask adds 5C (1.5g, 4.90mmol), dissolves with dichloromethane (40mL), add oxalyl chloride (1.04mL, 12.2mmol), DMF (1), stirring reaction 2h under room temperature, reactant liquor is evaporated off solvent, obtains 5D, standby.100mL round-bottomed flask adds 5E (827 μ L, 4.90mmol), dissolves with dichloromethane (10mL), stir under ice bath, add triethylamine (750 μ L, 5.39mmol), be added dropwise over 5D, drip and finish, react overnight under room temperature.Reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, and is spin-dried for, and the residue obtained separates purification through column chromatography (dichloromethane) and obtains white solid 5F (2.03g, productivity 88.3%).
50mL round-bottomed flask adds 5F (1.1g, 2.35mmol), toluene (6mL), phosphorus oxychloride (1.17mL), stirring reaction 2h in 110 DEG C of oil baths, it is cooled to room temperature, saturated sodium bicarbonate aqueous solution cancellation, extraction into ethyl acetate, water washing is added under ice bath, anhydrous sodium sulfate dries, and is spin-dried for and obtains grease.This grease methanol (15mL) dissolves, stir under room temperature, it is dividedly in some parts sodium borohydride (178mg, 4.70mmol), finishes, 20min is stirred under room temperature, reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, it is spin-dried for the residue obtained to separate purification through column chromatography (dichloromethane: methanol 100:1) and obtain colourless paste compound 5 (960mg, productivity 90.1%).1HNMR(400MHz,CDCl3) δ 7.82 7.77 (m, 2H), 7.36 7.30 (m, 3H), 7.25 7.15 (m, 2H), 6.98 6.91 (m, 1H), 6.62 (s, 1H), 6.58 (s, 1H), 4.31 (dd, J=9.5,4.0Hz, 1H), 3.86 (s, 3H), 3.80 (s, 3H), 3.31 3.20 (m, 2H), 3.09 2.99 (m, 1H), 2.91 (dd, J=14.0,9.7Hz, 1H), 2.80 (t, J=5.8Hz, 2H), 2.45 (s, 3H);MS(ESI)m/z[M+Na]+: 476.17.
Embodiment 6
50mL round-bottomed flask adds 6A (120mg, 0.265mmol), dissolve with methanol (10mL), add 37% formalin (0.5mL), 30min is stirred under room temperature, add anhydrous sodium sulfate, filter, filtrate adds sodium borohydride (100mg, 2.65mmol), 1h is stirred at room temperature, reactant liquor is spin-dried for, and adds water and extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, it is spin-dried for the residue that obtains to separate purification through preparation TLC (dichloromethane: methanol 20:1) and obtain colourless paste compound 6 (71mg, productivity 57.3%).1HNMR(400MHz,CDCl3) δ 7.80 7.75 (m, 2H), 7.35 7.30 (m, 2H), 7.16 7.05 (m, 3H), 6.98 6.91 (m, 1H), 6.53 (s, 1H), 6.12 (s, 1H), 3.83 (s, 3H), 3.79 (t, J=6.7Hz, 1H), 3.58 (s, 3H), 3.23 3.14 (m, 1H), 3.04 (dd, J=13.8,6.8Hz, 1H), 2.92 2.73 (m, 3H), 2.60 2.52 (m, 1H), 2.45 (s, 3H), 2.42 (s, 3H);MS(ESI)m/z[M-H]-: 466.11.
Embodiment 7
50mL round-bottomed flask adds 7A (80mg, 0.176mmol), it is dissolved in dichloromethane (10mL), add triethylamine (29 μ L, 0.212mmol), 7B (26 μ L, 0.194mmol), stirring 3h under room temperature, reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, organic facies anhydrous sodium sulfate dries, being spin-dried for, the residue obtained separates purification through preparation TLC (petroleum ether: ethyl acetate 2:1) and obtains compound as white solid 7 (82mg, productivity 76.2%).1HNMR(400MHz,CDCl3null)δ7.83–7.77(m,2H),7.39–7.31(m,3H),7.25–7.16(m,2H),7.15–7.03(m,4H),6.79–6.72(m,1H),6.60(s,1H),6.43(s,1H),5.21(dd,J=9.7,4.7Hz,1H),3.87(dd,J=14.2,4.9Hz,1H),3.81(s,3H),3.80(s,3H),3.64–3.53(m,1H),3.16(dd,J=14.1,4.7Hz,1H),2.96(dd,J=14.1,9.8Hz,1H),2.74–2.62(m,1H),2.59–2.49(m,1H),2.47(s,3H);MS(ESI)m/z[M+Na]+: 634.01.
Embodiment 8
50mL round-bottomed flask adds 8A (110mg, 0.243mmol), it is dissolved in dichloromethane (10mL), add triethylamine (51 μ L, 0.364mmol), 8B (31 μ L, 0.291mmol), stirring 3h under room temperature, reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, organic facies anhydrous sodium sulfate dries, being spin-dried for, the residue obtained separates purification through preparation TLC (petroleum ether: ethyl acetate 2:1) and obtains compound as white solid 8 (92mg, productivity 67.6%).1HNMR(400MHz,CDCl3null)δ7.81–7.75(m,2H),7.37–7.31(m,2H),7.24–7.12(m,3H),6.89–6.84(m,1H),6.58(s,1H),6.54(s,1H),4.97(dd,J=9.6,5.0Hz,1H),3.85(s,3H),3.81(dd,J=14.6,6.3Hz,1H),3.76(s,3H),3.55–3.45(m,1H),3.14(dd,J=14.1,5.1Hz,1H),3.11–3.01(m,1H),2.97(dd,J=14.2,9.6Hz,1H),2.61(dd,J=16.1,3.7Hz,1H),2.46(s,3H),2.43(s,6H);MS(ESI)m/z[M+H]+: 561.10.
Embodiment 9
100mL round-bottomed flask adds 9A (1.5g, 6.97mmol), dissolves with dichloromethane (40mL), add oxalyl chloride (893 μ L, 10.5mmol), DMF (1), stirring reaction 2h under room temperature, reactant liquor is evaporated off solvent, obtains 9B, standby.
100mL round-bottomed flask adds 9C (1.18mL, 6.97mmol), dissolves with dichloromethane (20mL), stir under ice bath, add triethylamine (1.07mL, 7.67mmol), be added dropwise over 9B, drip and finish, react overnight under room temperature.Reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, and is spin-dried for, and the residue obtained separates purification through column chromatography (dichloromethane) and obtains white solid 9D (1.85g, productivity 70.2%).
50mL round-bottomed flask adds 9D (900mg, 2.38mmol), toluene (5mL), phosphorus oxychloride (1.2mL), stirring reaction 2h in 110 DEG C of oil baths, it is cooled to room temperature, saturated sodium bicarbonate aqueous solution cancellation, extraction into ethyl acetate, water washing is added under ice bath, anhydrous sodium sulfate dries, and is spin-dried for and obtains grease.This grease methanol (20mL) dissolves, stir under room temperature, it is dividedly in some parts sodium borohydride (180mg, 4.76mmol), finishes, 20min is stirred under room temperature, reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, it is spin-dried for and obtains compound 9E, be directly used in next step reaction.
50mL round-bottomed flask adds 9E (213mg, 0.588mmol), is dissolved in dichloromethane (10mL), add triethylamine (123 μ L, 0.882mmol), 9F (127 μ L, 1.18mmol), stirring 3h under room temperature, reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, organic facies anhydrous sodium sulfate dries, it is spin-dried for, obtains colourless paste 9G, be directly used in next step reaction.
25mL round-bottomed flask adds 9G (309mg; 0.658mmol); palladium (8mg; 0.033mmol), 9H (24mg, 0.066mmol); potassium carbonate (182mg; 1.32mmol), DMA (6mL), stirs 10h in 130 DEG C of oil baths under nitrogen protection; it is cooled to room temperature; add water and extraction into ethyl acetate, collect organic facies, water washing; anhydrous sodium sulfate dries; being spin-dried for, the residue obtained separates purification through preparation TLC (petroleum ether: ethyl acetate 5:1) and obtains off-white color solid chemical compound 9 (40mg, productivity 15.7%).1HNMR(400MHz,CDCl3) δ 8.41 (d, J=7.8Hz, 1H), 7.35 7.22 (m, 3H), 6.68 (s, 1H), 4.58 (dd, J=13.5,4.4Hz, 1H), 3.96 3.87 (m, 4H), 3.66 (s, 3H), 3.23 3.13 (m, 1H), 3.10 2.93 (m, 3H), 2.80 (s, 6H), 2.70 2.62 (m, 1H);MS(ESI)m/z[M+H]+: 389.12.
Embodiment 10
100mL round-bottomed flask adds sodium hydroxide (2g), dissolves with water (30mL), be cooled to room temperature, add 10A (2.0g, 13.1mmol), stirring and dissolving, then it is dividedly in some parts 10B (2.76g, 14.5mmol), finish, stirred overnight at room temperature.Reactant liquor aqueous hydrochloric acid solution (2mol/L) regulates pH to 4, precipitates out solid, sucking filtration, water washing, collecting filter cake, filter cake dissolves with sodium hydrate aqueous solution (2mol/L) again, filters insoluble matter, the filtrate obtained regulates pH to 4 with aqueous hydrochloric acid solution (2mol/L), precipitate out solid, sucking filtration, water washing, obtain white solid 10C (1.42g, productivity 35.4%) after drying.
100mL round-bottomed flask adds 10C (1.4g, 4.57mmol), dissolves with dichloromethane (20mL), add oxalyl chloride (971 μ L, 11.4mmol), DMF (1), stirring reaction 2h under room temperature, reactant liquor is evaporated off solvent, obtains 10D, standby.100mL round-bottomed flask adds 10E (771 μ L, 4.57mmol), dissolves with dichloromethane (10mL), stir under ice bath, add triethylamine (699 μ L, 5.03mmol), be added dropwise over 10D, drip and finish, react overnight under room temperature.Reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, and is spin-dried for, and the residue obtained separates purification through column chromatography (dichloromethane) and obtains white solid 10F (655mg, productivity 30.6%).
50mL round-bottomed flask adds 10F (655mg, 1.40mmol), toluene (5mL), phosphorus oxychloride (700 μ L), stirring reaction 2h in 110 DEG C of oil baths, it is cooled to room temperature, saturated sodium bicarbonate aqueous solution cancellation, extraction into ethyl acetate, water washing is added under ice bath, anhydrous sodium sulfate dries, and is spin-dried for and obtains grease.This grease methanol (10mL) dissolves, stir under room temperature, be dividedly in some parts sodium borohydride (106mg, 2.80mmol), finish, stirring 20min under room temperature, reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, organic facies anhydrous sodium sulfate dries, it is spin-dried for and obtains light yellow paste 10G (590mg, productivity 92.9%), be directly used in next step reaction.
50mL round-bottomed flask adds 10G (80mg, 0.176mmol), dissolve with methanol (20mL), add 37% formalin (0.33mL), 30min is stirred under room temperature, add anhydrous sodium sulfate, filter, filtrate adds sodium borohydride (67mg, 1.76mmol), 1h is stirred at room temperature, reactant liquor is spin-dried for, and adds water and extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, it is spin-dried for the residue that obtains to separate purification through preparation TLC (dichloromethane: methanol 20:1) and obtain colourless paste compound 10 (47mg, productivity 57.1%).1HNMR(400MHz,CDCl3) δ 7.73 7.68 (m, 2H), 7.33 7.27 (m, 2H), 7.14 (t, J=7.8Hz, 1H), 6.96 6.90 (m, 1H), 6.88 6.79 (m, 2H), 6.56 (s, 1H), 5.94 (s, 1H), 3.84 (s, 3H), 3.71 3.64 (m, 1H), 3.56 (s, 3H), 3.26 3.13 (m, 2H), 2.89 2.75 (m, 3H), 2.66 2.56 (m, 1H), 2.50 (s, 3H), 2.43 (s, 3H);MS(ESI)m/z[M+H]+: 490.10.
Embodiment 11
50mL round-bottomed flask adds 11A (80mg, 0.176mmol), it is dissolved in dichloromethane (10mL), add triethylamine (29 μ L, 0.212mmol), 11B (26 μ L, 0.194mmol), stirring 3h under room temperature, reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, organic facies anhydrous sodium sulfate dries, being spin-dried for, the residue obtained separates purification through preparation TLC (petroleum ether: ethyl acetate 2:1) and obtains compound as white solid 11 (86mg, productivity 79.9%).1HNMR(400MHz,CDCl3) δ 7.75 7.71 (m, 2H), 7.42 7.37 (m, 1H), 7.36 7.27 (m, 4H), 7.19 7.11 (m, 2H), 6.94 6.89 (m, 1H), 6.82 (m, 2H), 6.44 (s, 1H), 6.14 (s, 1H), 5.02 (t, J=6.9Hz, 1H), 3.80 (s, 3H), 3.72 3.63 (m, 4H), 3.46 3.35 (m, 1H), 3.13 2.97 (m, 2H), 2.68 2.56 (m, 1H), 2.52 2.40 (m, 4H);MS(ESI)m/z[M+Na]+: 633.97.
Embodiment 12
50mL round-bottomed flask adds 12A (80mg, 0.176mmol), it is dissolved in dichloromethane (10mL), add triethylamine (37 μ L, 0.264mmol), 12B (57 μ L, 0.528mmol), stirring 3h under room temperature, reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, organic facies anhydrous sodium sulfate dries, being spin-dried for, the residue obtained separates purification through preparation TLC (petroleum ether: ethyl acetate 2:1) and obtains compound as white solid 12 (63mg, productivity 63.9%).1HNMR(400MHz,CDCl3null)δ7.75–7.70(m,2H),7.35–7.29(m,2H),7.19(t,J=7.8Hz,1H),7.04–6.99(m,1H),6.92–6.82(m,2H),6.58(s,1H),6.10(s,1H),4.83(t,J=7.0Hz,1H),3.84(s,3H),3.69(ddd,J=13.5,6.1,1.9Hz,1H),3.63(s,3H),3.39–3.28(m,1H),3.13(dd,J=13.5,6.9Hz,1H),3.06–2.94(m,2H),2.66–2.52(m,7H),2.44(s,3H);MS(ESI)m/z[M+H]+: 560.95.
Embodiment 13
100mL round-bottomed flask adds sodium hydroxide (3g), dissolves with water (30mL), be cooled to room temperature, add 13A (3.0g, 19.6mmol), stirring and dissolving, then it is dividedly in some parts 13B (4.14g, 21.8mmol), finish, stirred overnight at room temperature.Reactant liquor aqueous hydrochloric acid solution (2mol/L) regulates pH to 4, precipitates out solid, sucking filtration, water washing, collecting filter cake, filter cake dissolves with sodium hydrate aqueous solution (2mol/L) again, filters insoluble matter, the filtrate obtained regulates pH to 4 with aqueous hydrochloric acid solution (2mol/L), precipitate out solid, sucking filtration, water washing, obtain white solid 13C (2.2g, productivity 36.6%) after drying.
100mL round-bottomed flask adds 13C (1.4g, 4.57mmol), dissolves with dichloromethane (20mL), add oxalyl chloride (971 μ L, 11.4mmol), DMF (1), stirring reaction 2h under room temperature, reactant liquor is evaporated off solvent, obtains 13D, standby.100mL round-bottomed flask adds 13E (771 μ L, 4.57mmol), dissolves with dichloromethane (10mL), stir under ice bath, add triethylamine (699 μ L, 5.03mmol), be added dropwise over 13D, drip and finish, react overnight under room temperature.Reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, and is spin-dried for, and the residue obtained separates purification through column chromatography (dichloromethane) and obtains white solid 13F (633mg, productivity 29.5%).
50mL round-bottomed flask adds 13F (633mg, 1.35mmol), toluene (5mL), phosphorus oxychloride (675 μ L), stirring reaction 2h in 110 DEG C of oil baths, it is cooled to room temperature, saturated sodium bicarbonate aqueous solution cancellation, extraction into ethyl acetate, water washing is added under ice bath, anhydrous sodium sulfate dries, and is spin-dried for and obtains grease.This grease methanol (10mL) dissolves, stir under room temperature, be dividedly in some parts sodium borohydride (102mg, 2.70mmol), finish, stirring 20min under room temperature, reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, organic facies anhydrous sodium sulfate dries, it is spin-dried for and obtains colourless paste 13G (574mg, productivity 93.7%), be directly used in next step reaction.
50mL round-bottomed flask adds 13G (80mg, 0.176mmol), it is dissolved in dichloromethane (10mL), add triethylamine (29 μ L, 0.212mmol), 13H (26 μ L, 0.194mmol), stirring 3h under room temperature, reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, organic facies anhydrous sodium sulfate dries, being spin-dried for, the residue obtained separates purification through preparation TLC (petroleum ether: ethyl acetate 2:1) and obtains compound as white solid 13 (85mg, productivity 79.0%).1HNMR(400MHz,CDCl3) δ 7.73 7.66 (m, 2H), 7.41 7.29 (m, 5H), 7.20 7.12 (m, 1H), 7.02 6.94 (m, 2H), 6.90 6.84 (m, 2H), 6.42 (s, 1H), 6.14 (s, 1H), 5.03 (t, J=6.6Hz, 1H), 3.80 (s, 3H), 3.72 3.58 (m, 4H), 3.46 3.34 (m, 1H), 3.14 (dd, J=13.5,6.3Hz, 1H), 3.04 (dd, J=13.5,7.1Hz, 1H), 2.63 2.51 (m, 1H), 2.50 2.37 (m, 4H);MS(ESI)m/z[M+H]+: 633.85.
Embodiment 14
50mL round-bottomed flask adds 14A (80mg, 0.176mmol), dissolve with methanol (20mL), add 37% formalin (0.33mL), 30min is stirred under room temperature, add anhydrous sodium sulfate, filter, filtrate adds sodium borohydride (67mg, 1.76mmol), 1h is stirred at room temperature, reactant liquor is spin-dried for, and adds water and extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, it is spin-dried for the residue that obtains to separate purification through preparation TLC (dichloromethane: methanol 20:1) and obtain colourless paste compound 14 (48mg, productivity 58.3%).1HNMR(400MHz,CDCl3) δ 7.73 7.67 (m, 2H), 7.34 7.28 (m, 2H), 7.05 6.98 (m, 2H), 6.90 6.84 (m, 2H), 6.55 (s, 1H), 5.93 (s, 1H), 3.83 (s, 3H), 3.78 (dd, J=7.8,4.7Hz, 1H), 3.55 (s, 3H), 3.35 3.18 (m, 2H), 2.90 2.77 (m, 3H), 2.68 2.59 (m, 1H), 2.56 (s, 3H), 2.45 (s, 3H);MS(ESI)m/z[M+Na]+: 490.00.
Embodiment 15
50mL round-bottomed flask adds 15A (80mg, 0.176mmol), it is dissolved in dichloromethane (10mL), add triethylamine (37 μ L, 0.264mmol), 15B (189 μ L, 1.76mmol), stirring 3h under room temperature, reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, organic facies anhydrous sodium sulfate dries, being spin-dried for, the residue obtained separates purification through preparation TLC (petroleum ether: ethyl acetate 2:1) and obtains compound as white solid 15 (40mg, productivity 40.5%).1HNMR(400MHz,CDCl3) δ 7.76 7.68 (m, 2H), 7.38 7.30 (m, 2H), 7.12 7.04 (m, 2H), 6.95 6.88 (m, 2H), 6.58 (s, 1H), 6.12 (s, 1H), 4.87 (t, J=6.8Hz, 1H), 3.84 (s, 3H), 3.73 3.60 (m, 4H), 3.40 3.27 (m, 1H), 3.17 (dd, J=13.5,6.5Hz, 1H), 3.07 2.93 (m, 2H), 2.68 2.53 (m, 7H), 2.46 (s, 3H);MS(ESI)m/z[M+Na]+: 583.08.
Embodiment 16
100mL round-bottomed flask adds 16A (710mg, 3.30mmol), dissolves with dichloromethane (20mL), add oxalyl chloride (703 μ L, 8.25mmol), DMF (1), stirring reaction 2h under room temperature, reactant liquor is evaporated off solvent, obtains 16B, standby.100mL round-bottomed flask adds 16C (850mg, 3.30mmol), dissolves with dichloromethane (20mL), stir under ice bath, add triethylamine (505 μ L, 3.63mmol), be added dropwise over 16B, drip and finish, react overnight under room temperature.Reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, and is spin-dried for, and the residue obtained separates purification through column chromatography (dichloromethane) and obtains white solid 16D (567mg, productivity 37.8%).
50mL round-bottomed flask adds 16D (560mg, 1.23mmol), toluene (6mL), phosphorus oxychloride (617 μ L), stirring reaction 2h in 110 DEG C of oil baths, it is cooled to room temperature, saturated sodium bicarbonate aqueous solution cancellation, extraction into ethyl acetate, water washing is added under ice bath, anhydrous sodium sulfate dries, and is spin-dried for and obtains grease.This grease methanol (10mL) dissolves, stir under room temperature, it is dividedly in some parts sodium borohydride (93mg, 2.46mmol), finishes, 20min is stirred under room temperature, reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, it is spin-dried for and obtains colorless oil 16E (410mg, productivity 76.1%).
50mL round-bottomed flask adds 16E (410mg, 0.936mmol), is dissolved in dichloromethane (10mL), add triethylamine (156 μ L, 1.12mmol), methylchloroformate 16F (87 μ L, 1.12mmol), 2h is stirred under room temperature, reactant liquor is spin-dried for, and residue adds water and extraction into ethyl acetate, and organic facies anhydrous sodium sulfate dries, it is spin-dried for, obtains colourless paste 16G.It is directly used in next step reaction.
50mL round-bottomed flask adds 16G (448mg; 0.903mmol); palladium (10mg; 0.045mmol), 16H (33mg, 0.090mmol); potassium acetate (177mg; 1.81mmol), DMA (6mL), stirs 10h in 130 DEG C of oil baths under nitrogen protection; it is cooled to room temperature; add water and extraction into ethyl acetate, collect organic facies, water washing; anhydrous sodium sulfate dries; being spin-dried for, the residue obtained separates purification through column chromatography (petroleum ether: ether 4:1) and obtains white solid 16I (202mg, productivity 53.8%).
100mL round-bottomed flask adds 16I (200mg, 0.481mmol), anhydrous THF (20mL); stirring and dissolving is placed in ice bath, is slowly added to lithium aluminium hydride (110mg, 2.89mmol); finish, at room temperature stir 10min, in 70 DEG C of oil baths, under nitrogen protection, stir 10h; it is cooled to room temperature, under stirring, drips methanol, saturated sodium bicarbonate aqueous solution cancellation successively; continue stirring 20min, sucking filtration, washing with alcohol; merging filtrate, is spin-dried for, and obtains colourless paste 16J.It is directly used in next step reaction.
100mL round-bottomed flask is sequentially added into 16J (150mg, 0.404mmol), palladium carbon (50mg), methanol (12mL), room temperature under an atmosphere of hydrogen, atmospheric agitation 4h.Reactant liquor sucking filtration, methanol washs, and merging filtrate is spin-dried for, obtains light brown paste 16K.It is directly used in next step reaction.
50mL round-bottomed flask adds compound 16K (120mg, 0.427mmol), chloroform (6mL), between fluorophenylsulfonyl chloride 16L (227 μ L, 1.71mmol), pyridine (0.2mL), reacting 10h in 65 DEG C of oil baths, reactant liquor is spin-dried for, and adds saturated sodium bicarbonate aqueous solution in residue, extraction into ethyl acetate, merging organic facies, water washing, anhydrous sodium sulfate dries, the residue obtained after being spin-dried for separates purification through preparation TLC (petroleum ether: ethyl acetate 1:1) and obtains light brown paste compound 16 (46mg, productivity 24.5%).1HNMR(400MHz,CDCl3) δ 8.07 8.00 (m, 1H), 7.77 7.72 (m, 1H), 7.72 7.67 (m, 1H), 7.54 (td, J=8.1,5.2Hz, 1H), 7.43 7.36 (m, 1H), 7.29 7.20 (m, 3H), 6.93 (s, 1H), 3.45 (s, 3H), 3.16 2.98 (m, 4H), 2.68 (dd, J=16.1,3.3Hz, 1H), 2.59 (t, J=13.5Hz, 1H), 2.56 2.45 (m, 4H);MS(ESI)m/z[M+H]+: 440.14.
Embodiment 17
Experimental program and pertinent literature with reference to above example 16 grade prepare compound 17,1HNMR (400MHz, MeOD) δ 7.84 7.77 (m, 1H), 7.48 7.38 (m, 2H), 7.36 7.19 (m, 4H), 7.17 7.11 (m, 1H), 7.04 (s, 1H), 4.18 (dd, J=13.9,2.9Hz, 1H), 3.90 3.82 (m, 1H), 3.79 (s, 3H), 3.61 3.49 (m, 1H), 3.48 3.37 (m, 2H), 3.27 3.11 (m, 4H), 2.80 (t, J=13.7Hz, 1H);MS(ESI)m/z[M+H]+: 440.16.
Embodiment 18
Experimental program and pertinent literature with reference to above example prepare compound 18, MS (ESI) m/z [M+H]+: 466.28.
Embodiment 19
Experimental program and pertinent literature with reference to above example prepare compound 19, MS (ESI) m/z [M+H]+: 466.35.
Embodiment 20
Experimental program and pertinent literature with reference to above example prepare compound 20, MS (ESI) m/z [M+H]+: 466.21.
Embodiment 21
Experimental program and pertinent literature with reference to above example prepare compound 21, MS (ESI) m/z [M+H]+: 466.04.
Embodiment 22
Experimental program and pertinent literature with reference to above example prepare compound 22, MS (ESI) m/z [M+H]+: 435.23.
Embodiment 23
Experimental program and pertinent literature with reference to above example prepare compound 23, MS (ESI) m/z [M+H]+: 470.22.
Embodiment 24
Experimental program and pertinent literature with reference to above example prepare compound 24, MS (ESI) m/z [M+H]+: 478.20.
Embodiment 25
Experimental program and pertinent literature with reference to above example prepare compound 25, MS (ESI) m/z [M+H]+: 461.11.
Embodiment 26
Experimental program and pertinent literature with reference to above example prepare compound 26, MS (ESI) m/z [M+H]+: 512.09.
Embodiment 27
Experimental program and pertinent literature with reference to above example prepare compound 27, MS (ESI) m/z [M+H]+: 419.26.
Embodiment 28
Experimental program and pertinent literature with reference to above example prepare compound 28, MS (ESI) m/z [M+H]+: 463.10.
Embodiment 29
Experimental program and pertinent literature with reference to above example prepare compound 29, MS (ESI) m/z [M+H]+: 435.14.
Embodiment 30
Experimental program and pertinent literature with reference to above example prepare compound 30, MS (ESI) m/z [M+H]+: 449.05.
Embodiment 31
Experimental program and pertinent literature with reference to above example prepare compound 31, MS (ESI) m/z [M+H]+: 482.21.
Embodiment 32
Experimental program and pertinent literature with reference to above example prepare compound 32, MS (ESI) m/z [M+H]+: 495.11.
Embodiment 33
Experimental program and pertinent literature with reference to above example prepare compound 33, MS (ESI) m/z [M+H]+: 495.22.
Embodiment 34
Experimental program and pertinent literature with reference to above example prepare compound 34, MS (ESI) m/z [M+H]+: 482.10.
Embodiment 35
Experimental program and pertinent literature with reference to above example prepare compound 35, MS (ESI) m/z [M+H]+: 482.32.
Embodiment 36
Experimental program and pertinent literature with reference to above example prepare compound 36, MS (ESI) m/z [M+H]+: 496.13.
Embodiment 37
Experimental program and pertinent literature with reference to above example prepare compound 37, MS (ESI) m/z [M+H]+: 481.25.
Embodiment 38
Experimental program and pertinent literature with reference to above example prepare compound 38, MS (ESI) m/z [M+H]+: 481.10.
Embodiment 39
Experimental program and pertinent literature with reference to above example prepare compound 39, MS (ESI) m/z [M+H]+: 495.17.
Embodiment 40
Experimental program and pertinent literature with reference to above example prepare compound 40, MS (ESI) m/z [M+H]+: 482.13.
Embodiment 41
Experimental program and pertinent literature with reference to above example prepare compound 41, MS (ESI) m/z [M+H]+: 468.22.
Embodiment 42
Experimental program and pertinent literature with reference to above example prepare compound 42, MS (ESI) m/z [M+H]+: 510.16.
Embodiment 43
Experimental program and pertinent literature with reference to above example prepare compound 43, MS (ESI) m/z [M+H]+: 468.23.
Embodiment 44
Experimental program and pertinent literature with reference to above example prepare compound 44, MS (ESI) m/z [M+H]+: 495.34.
Embodiment 45
Experimental program and pertinent literature with reference to above example prepare compound 45, MS (ESI) m/z [M+H]+: 468.22.
Embodiment 46
Experimental program and pertinent literature with reference to above example prepare compound 46, MS (ESI) m/z [M+H]+: 495.21.
Embodiment 47
Experimental program and pertinent literature with reference to above example prepare compound 47, MS (ESI) m/z [M+H]+: 468.25.
Embodiment 48
Experimental program and pertinent literature with reference to above example prepare compound 48, MS (ESI) m/z [M+H]+: 495.07.
Embodiment 49
Experimental program and pertinent literature with reference to above example prepare compound 49, MS (ESI) m/z [M+H]+: 438.20.
Embodiment 50
Experimental program and pertinent literature with reference to above example prepare compound 50, MS (ESI) m/z [M+H]+: 452.34.
Embodiment 51
Experimental program and pertinent literature with reference to above example prepare compound 51, MS (ESI) m/z [M+H]+: 440.54.
Reference compound
Reference literature WO2010075469 prepares following compounds, and the spectroscopy data of following compound is consistent with document:
Reference literature WO2014150395 prepares following compounds, and the spectroscopy data of following compound is consistent with document:
Part of compounds biological test result of the present invention
One, the fluorescent quantitative PCR experiment detection medicine impact on hepatocyte PCSK9 gene expression dose
This experiment purpose is the reflection compound inhibitory action to PCSK9 gene expression, and compound is more strong to the inhibitory action of PCSK9 gene expression, it was shown that the potential fat-reducing effect of compound is more strong.
The detection medicine effect to HepG2 cell PCSK9mRNA:
By HepG2 cell (ATCC), by every hole 7 × 105The density of cells/well is seeded to 6 orifice plates, 37 DEG C, 5%CO2Overnight incubation.Next day, change liquid and add medicine to be measured and positive drug and process 24 hours.Extracting total serum IgE with Trizol reagent (Invitrogen), RNase-FreeDNase (Promega) processes.Every part of sample takes 1ugRNA, becomes cDNA as the template of real-time fluorescence quantitative PCR with M-MLV reverse transcriptase (Promega) reverse transcription.Use the PCSK9 quantification PCR primer through verifying, β-Actin quantification PCR primer as the primer of PCSK9 and reference gene β-Actin.The quantitative PCR reaction system of each sample is prepared with template, primer, PowerSYBRGreenPCRMasterMix (Invitrogen), quantitative PCR apparatus CFX96Real-TimePCRDetectionSystem (Bio-Rad) carries out real-time fluorescence quantitative PCR reaction by PCR instrument device description requirement, it is thus achieved that expression data.Δ Δ CT method is adopted to process expression data, with β-Actin for internal reference, the PCSK9 expression of blank is set as 1, try to achieve PCSK9 in all the other samples and, relative to the relative expression quantity (multiple relative to comparison) of comparison, assess the medicine impact on hepatocyte PCSK9 gene expression dose with this.
Experiments show that: the compounds of this invention, for instance: 1,2,4,5,6,7,8,10,11,12,13,14,15,16 etc., it is possible to PCSK9mRNA is expressed and plays strong inhibitory action.
Two, LDL uptake ratio test experiments:
The purpose of this experiment is the reflection compound effect to reducing LDL on a cellular level.LDL level crosses high energy atherogenicity.This experiment directly detects the ability of hepatocyte picked-up LDL from cellular level, can directly reflect the lipid-lowering effect of compound.
LDL uptake ratio cell model:
Surface of hepatocytes expresses ldl receptor, has the ability of picked-up LDL.Add the LDL (Dil-LDL) of fluorescent material Dil labelling in the medium, under fluorescence microscope, HepG2 hepatoma carcinoma cell be can be observed Dil-LDL is absorbed in cell.Medicine can make the amount of surface of hepatocytes ldl receptor increase thus strengthening the hepatocyte picked-up ability to LDL, therefore can be used on the fluorescence intensity that basis of microscopic observation arrives and evaluates sample hepatocyte absorbs the impact of LDL ability.
Cellar culture HepG2 cell (ATCC), is seeded to 96 orifice plates by the density of 2.5 × 104 cells in every hole, 37 DEG C, 5%CO2Overnight incubation.Next day, abandon supernatant, add sample and positive drug processes 20 hours.Abandoning supernatant, every hole adds the fresh culture of the epipolic Dil-LDL containing 2 μ g/ml (Invitrogen), at 37 DEG C, and 5%CO2Continue under condition to hatch 4 hours.Abandon supernatant, with PBS washed cell 2 times, change fresh culture, under fluorescence microscope (LeicaDMILLEDMicrosystems), observe the fluorescence intensity of every porocyte.To be not added with normal cell that sample and Dil-LDL process as negative control.Evaluate sample by the fluorescence intensity examined under a microscope and hepatocyte is absorbed the impact of LDL ability, and in addition classification, it is simple to compare.Stage division is as follows:
-represent compared with normal cell controls, without the fluorescence intensity increased;
+ represent compared with normal cell controls, the fluorescence intensity slightly increased;
++ represent compared with normal cell controls, the fluorescence intensity of medium increase;
+++ represent compared with normal cell controls, the fluorescence intensity strongly increased;
++++represent compared with normal cell controls, the fluorescence intensity strongly increased.
Test result indicate that: the compounds of this invention can strengthen the hepatocyte picked-up ability to LDL significantly.With compound C1 representative in document WO2010075469 and document WO2014150395, C2, C3, C4, C5 (structural formula sees above) compares, the hepatocyte that relatively low concentration the compounds of this invention processes is used to show the notable ability absorbing LDL, and the hepatocyte that reference compound processed at low concentration, to LDL almost without picked-up ability.Illustrate that the activity of the compounds of this invention increase hepatocyte picked-up LDL is significantly stronger than reference compound C1, C2, C3, C4, C5.
Three, the compound dual activation test experimental result to ERK and AMPK signal pathway:
With the compounds of this invention, HepG2 cell is processed, and detect the activation of ERK and AMPK.
Result shows: than undressed compared with control cells, dramatically increases at phosphorylated in the cell of compound treatment and activation ERK and AMPK.Including compound 1,2,4,5,6,7,8,10,11,12,13,14,15,16 etc..
Further, adopting the insulin resistant Mice model of obesity of High fat diet induction, the compounds of this invention has blood sugar lowering and reduces the effect of body weight, has and is obviously improved carbohydrate tolerance and insulin resistant, strengthens the feature of insulin sensitivity.
On the other hand, existing Research Literature shows: the activation of AMPK can suppress the downstream kinase of mTOR and Akt, and prompting AMPK/Akt/mTOR is probably the desirable target spot of oncotherapy.In existing Research Literature, cell experiment and zoopery are all pointed out, mTOR signal path can suppress the growth of tumor cell after suppressing, ERK and the AMPK of the compounds of this invention activation, can affecting the downstream kinase of mTOR and Akt further, prompting the compounds of this invention can be developed further into as antitumor drug.
Four, blood fat reducing experiment in SD rat model body:
Model is set up: customization fed with high SD rat, and normal group grows diet with common size Mus, gathers animal serum after 4 weeks, and Testing index changes.The rat of high lipid food induction is compared with normal rats, and in serum, LDL-C, TC equal size is increased significantly and has significant difference, it was demonstrated that high blood lipid model is successfully established.
Acute toxicity test: adopting single dose successive administration 7 days, test-compound, under the dosage of 500mg/kg, does not show apparent side effect.
Test group mediating recipe amount design: Normal group, hyperlipidemia model matched group, simvastatin group (8mg/kg), compound 16 groups (50mg/kg), compound 17 groups (50mg/kg).
Size of animal: often group 10.
Route of administration: oral administration gavage.
Administration frequency: once a day.
Administration time: 4 weeks.
Serum Indexes measures: after being administered 4 weeks, takes animal blood, is measured.
Measurement result induction and conclusion such as Fig. 2, Fig. 3, Fig. 4, Fig. 5.
The result of Fig. 2, Fig. 3, Fig. 4, Fig. 5 shows: the compounds of this invention 16, and compound 17 all can significantly reduce LDL-C and the TC of animal pattern.Fig. 4 and Fig. 5 shows, glutamate pyruvate transaminase and the glutamic oxaloacetic transaminase, GOT level of hyperlipidemia model group and simvastatin treated animal have significant rising, show abnormal liver function, but, the compounds of this invention, while showing notable internal Lipid-lowering activities, does not increase glutamate pyruvate transaminase and glutamic oxaloacetic transaminase, GOT level, compound 16, the glutamate pyruvate transaminase of compound 17 animal is consistent with normal diet treated animal with glutamic oxaloacetic transaminase, GOT level.Illustrate that the compounds of this invention is while blood fat reducing, liver is not caused damage by prompting, but simvastatin is while blood fat reducing, laboratory animal glutamate pyruvate transaminase and glutamic oxaloacetic transaminase, GOT level raise, illustrate that the animal pattern liver function taking simvastatin receives damage, also reveal that the obvious hepatotoxicity of statins.
Five, SD rat model nonalcoholic steatohepatitis experiment:
Zoologize explanation: what this experiment adopted zoologize uses animal for above-mentioned " in SD rat model body blood fat reducing experiment ", after animal serum index study completes, animal is put to death and dissects, take animal livers tissue, part formalin is fixed, partly-80 DEG C of freezen protective, carry out staining pathologic section (H&E dyeing, oil red-O dyeing) and check after being fixed for more than 48hr.Pay close attention to liver structure integrity, inflammatory cell infiltration and the fatty liver order of severity, and carry out (standards of grading: 0 grade: normal of marking;1 grade: < 20%;2 grades: 20-40%;3 grades: 40-60%;4 grades: 60-80%;5 grades: > 80%).Result is shown in following table.
Experimental animal group | Empty bag degeneration | Inflammation | Fat | Hyperemia under tunicle |
Intact animal | 0 | 0 | 0 | 0 |
High fat matched group | 4 | 3 | 4 | 3 |
Simvastatin group | 4 | 3 | 4 | 2 |
Compound 16 groups | 1 | 0 | 0 | 0 |
Compound 17 groups | 0 | 0 | 1 | 1 |
Result shows, hyperlipidemia model group is compared with normal group, in liver, the volume of adipose cell significantly increases, Macrovesicular steatosis occurs, fatty builds up the heavy damage organizational structure of liver, causes liver vacuolar degeneration, and with massive inflammatory cells infiltrated, above phenomenon shows, nonalcoholic steatohepatitis modeling success.After animal gavage takes part of compounds of the present invention, marking from vacuolar degeneration, compound 16, liver structure is all had certain protective effect by compound 17, and the hepar damnification caused due to adipose cell obtains certain reparation, reduces vacuolar degeneration degree;Compound 16, compound 17 can also significantly reduce inflammatory cell infiltration, reduces inflammation degree, and gathering and the adipose cell volume that can reduce fat increase, and liver fat degree alleviates.But, simvastatin treated animal liver anatomical, its liver structure integrity, inflammatory cell infiltration are consistent with hyperlipidemia model group with the fatty liver order of severity, and fatty liver symptom is not alleviated.The compounds of this invention 16, liver organization is all had certain protective effect by compound 17, and the compounds of this invention has the medical value for the treatment of fatty liver.
Above two experiments " in SD rat model body blood fat reducing experiment " and " experiment of SD rat model nonalcoholic steatohepatitis ", disclose the compounds of this invention and have a characteristic that
(1), the compounds of this invention show Lipid-lowering activities, without influence on liver normal function.In safe-dosaging limits, the compounds of this invention embodies the activity of internal blood fat reducing, does not cause the rising of rat transaminase level, and liver is not caused damage by prompting.But, simvastatin fat-reducing medicament, while showing Lipid-lowering activities, further such that the rising of animal transaminase level, illustrate that normal liver function receives damage, show obvious hepatotoxicity.The compounds of this invention blood fat reducing but do not affect the feature of liver function, in clinical practice, prompting the compounds of this invention has comparatively significant security advantages than statins.
(2), the compounds of this invention hyperlipidemia model Animal fat liver symptom is had potential therapeutical effect, and the lipid lowerers such as Statins do not have above curative effect.Can be seen that from " experiment of SD rat model nonalcoholic steatohepatitis ", the compounds of this invention reduces inflammation degree, gathering and the adipose cell volume that can reduce fat increase, liver fat degree alleviates, the hepar damnification that adipose cell causes obtains certain reparation, reduces vacuolar degeneration degree.But, simvastatin treated animal liver anatomical, its liver structure integrity, inflammatory cell infiltration are consistent with hyperlipidemia model group with the fatty liver order of severity, and fatty liver symptom is not alleviated.
Comprehensive above internal and Pharmacodynamics in vitro is tested, can be seen that, the compounds of this invention effect for reducing fat mechanism, it is different from existing listing fat-reducing medicament (such as: Statins, fibrates etc.), its excellent Lipid-lowering activities and its good security features, and the potential therapeutic value in fatty liver is treated, be expected to become vast cardiovascular patient and obtain the good fat-reducing medicament of new generation treating income.
Claims (12)
1. the compound of Formula V
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof;Wherein:
A is nitrogen-atoms, or carbon atom;
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10Selected from hydrogen, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ",-OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, the substituent group of heterocyclic radical or cycloheteroalkylalkyl is replaced;Or R4And R5It is directly connected to by chemical bond;
R11, R12, R13, R14, R15Hydrogen independently, halogen, that be substituted or be unsubstituted silica-based, amino, nitro, oxygen base, sulfenyl, sulfuryl, cyano group, carbonyl, sulfonyloxy, phosphorus acyloxy, alkyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl;
M=0,1,2;
N=1,2,3;
Q=0,1,2,3,4;
T=0,1,2,3.
2. general formula compound compound (V) according to claim 1, its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, including general formula compound (VI),
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, wherein:
A is nitrogen-atoms, or carbon atom;
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10Selected from hydrogen, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ",-OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, the substituent group of heterocyclic radical or cycloheteroalkylalkyl is replaced;Or R4And R5It is directly connected to by chemical bond;
R11, R12, R13, R14, R15, R16, R17Hydrogen independently, halogen, that be substituted or be unsubstituted silica-based, amino, nitro, oxygen base, sulfenyl, sulfuryl, cyano group, carbonyl, sulfonyloxy, phosphorus acyloxy, alkyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl;
M=0,1,2;
N=1,2,3;
Q=0,1,2,3,4.
3. general formula compound compound (VI) according to claim 2, its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, wherein, R11, R12, R13, R14, R15, R16, R17It is-H independently, halogen, alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl;
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10It is-H independently, halogen ,-OH ,-NO2,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ;-OC (O) OR ' ,-OC (O) NR ' R ", replacement or the amino that is unsubstituted, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl, be further selected from including:
R27Selected from phenyl, C1-12Alkyl, ring (C3-8) alkyl, thienyl, furyl, imidazole radicals, pyridine radicals, pyrimidine radicals, pyridazinyl, quinolyl, isoquinolyl, phenylacetylene base, benzyl, styryl, naphthyl, substituted-amino, morpholinyl, piperidyl, N methyl piperazine base, nafoxidine base, hexahydropyridine base, Camphora alkyl, p-methylphenyl
Wherein, C1-6Alkyl is optionally replaced by 0 to 13 substituent group,
Thienyl, furyl and imidazole radicals are optionally replaced by 0 to 3 substituent group,
Pyridine radicals is optionally replaced by 0 to 4 substituent group,
Pyrimidine radicals and pyridazinyl are optionally replaced by 0 to 3 substituent group,
Phenyl is optionally replaced by 0 to 5 substituent group,
Quinolyl and isoquinolyl naphthyl are selected for a post and are replaced by 0 to 6 substituent group,
Naphthyl is selected for a post and is replaced by 0 to 7 substituent group,
Above substituent group is selected from: hydroxyl, halogen, cyano group, nitro ,-COOH, carboxylic acid ester groups, replace or be unsubstituted silica-based, amino, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl;
R28Selected from hydrogen, the alkyl replacing or being unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl.
4. general formula compound compound (V) according to claim 1, its stereoisomer, its tautomer, its solvate and medicinal acceptable salt, wherein R4And R5It is directly connected to by chemical bond, including general formula compound (VII),
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, wherein:
A is nitrogen-atoms, or carbon atom;
R1, R2, R3, R6, R7, R8, R9, R10Selected from hydrogen, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ",-OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, the substituent group of heterocyclic radical or cycloheteroalkylalkyl is replaced;
R11, R12, R13, R14, R15Hydrogen independently, halogen, that be substituted or be unsubstituted silica-based, amino, nitro, oxygen base, sulfenyl, sulfuryl, cyano group, carbonyl, sulfonyloxy, phosphorus acyloxy, alkyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl;
M=0,1,2;
N=1,2,3;
Q=0,1,2,3,4;
T=0,1,2,3.
5. general formula compound compound (V) according to claim 1, its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, including general formula compound (VIII),
Its stereoisomer, its tautomer, its solvate and medicinal acceptable salt thereof, wherein:
A is nitrogen-atoms, or carbon atom;
R1, R2, R3, R6, R7, R8, R9, R10Selected from hydrogen, halogen ,-OH ,-NR ' R " ,-NO2,-Si (R ')3,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ,-OC (O) OR ' ,-OC (O) NR ' R " ,-S (O)mR ' ,-S (O)nNR ' R " ,-OS (O)nR ' ,-OS (O)nNR ' R ",-OS(O)nNR ' (C=O) NR ' R " ,-S (O)nNR ' (C=O) NR ' R " ,-NR ' S (O)nR " ,-NR ' S (O)nNR ' R ", alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, the substituent group of heterocyclic radical or cycloheteroalkylalkyl is replaced;
R11, R12, R13, R14, R15, R16, R17Hydrogen independently, halogen, that be substituted or be unsubstituted silica-based, amino, nitro, oxygen base, sulfenyl, sulfuryl, cyano group, carbonyl, sulfonyloxy, phosphorus acyloxy, alkyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl;
M=0,1,2;
N=1,2,3;
Q=0,1,2,3,4.
6. general formula compound compound (VIII) according to claim 4, wherein, R11, R12, R13, R14, R15, R16, R17It is-H independently, halogen, alkyl that is that be substituted or that be unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl;
R1, R2, R3, R6, R7, R8, R9, R10It is-H independently, halogen ,-OH ,-NO2,-CN ,-(CH2)0-6COOR ' ,-C (O) R ' ,-OC (O) R ' ,-C (O) NR ' R " ;-OC (O) OR ' ,-OC (O) NR ' R ", replacement or the amino that is unsubstituted, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl, be further selected from including:
R27Selected from phenyl, C1-12Alkyl, ring (C3-8) alkyl, thienyl, furyl, imidazole radicals, pyridine radicals, pyrimidine radicals, pyridazinyl, quinolyl, isoquinolyl, phenylacetylene base, benzyl, styryl, naphthyl, substituted-amino, morpholinyl, piperidyl, N methyl piperazine base, nafoxidine base, hexahydropyridine base, Camphora alkyl, p-methylphenyl
Wherein, C1-6Alkyl is optionally replaced by 0 to 13 substituent group,
Thienyl, furyl and imidazole radicals are optionally replaced by 0 to 3 substituent group,
Pyridine radicals is optionally replaced by 0 to 4 substituent group,
Pyrimidine radicals and pyridazinyl are optionally replaced by 0 to 3 substituent group,
Phenyl is optionally replaced by 0 to 5 substituent group,
Quinolyl and isoquinolyl naphthyl are selected for a post and are replaced by 0 to 6 substituent group,
Naphthyl is selected for a post and is replaced by 0 to 7 substituent group,
Above substituent group is selected from: hydroxyl, halogen, cyano group, nitro ,-COOH, carboxylic acid ester groups, replace or be unsubstituted silica-based, amino, alkyl, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl;
R28Selected from hydrogen, the alkyl replacing or being unsubstituted, alkoxyl, thiazolinyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl alkyl, heterocyclic radical or cycloheteroalkylalkyl.
7. the compound according to claim 1~6, this compound is selected from following compound, but is not limited to following compound range:
Or its medicinal acceptable salt.
8. preparing a logical compound shown in formula V, its stereoisomer, its tautomer, the method for its solvate and medicinal acceptable salt thereof described in claim 1, it comprises the following steps:
Above syntheti c route describes as follows: X1 and X2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.X1 and X2, under certain reaction condition, obtains compounds X 3 by certain amide method of attachment, and what intermediate X 3 was reacted under the effect of dehydrant obtains X4, in intermediate X 4, carbon-to-nitrogen double bon is after reducing agent effect, nitrogen-atoms occurs coupled reaction to obtain compound V further, wherein A, R1~R15, q, t defines with claim 1.
9. preparing the compound shown in formula described in claim 4 (VII), its stereoisomer, its tautomer, the method for its solvate and medicinal acceptable salt thereof, it comprises the following steps:
Above syntheti c route describes as follows: Y1 and Y2 is the starting material of the program, it is possible to obtained by commercially available prod, or the method according to bibliographical information prepares.Y1 and Y2 is under certain reaction condition, compound Y3 is obtained by amide method of attachment, what intermediate Y3 reacted under the effect of dehydrant obtains Y4, in intermediate Y4, carbon-to-nitrogen double bon is after reducing agent effect, the further coupled reaction of nitrogen-atoms obtains compound Y5, intermediate Y5 occur further point in cyclization be obtained by reacting compound VII, wherein A, R1~R4, R6~R15, q, t defines with claim 1.
10. a pharmaceutical composition, its compound comprising any one in claim 1 to 7 and pharmaceutically acceptable carrier.
11. any one compound is used for the purposes reducing in the medicine of the lipid levels of patients blood plasma and/or liver in preparation in claim 1 to 7.
12. any one compound is used for treating type ii diabetes in preparation in claim 1 to 7, hyperglycemia, obesity, insulin resistance, antitumor, and treatment hyperlipemia, hypercholesterolemia, hypertriglyceridemia, the disease of fatty degeneration of liver and metabolism syndrome composition or the purposes in the medicine of the patient's condition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015100133258 | 2015-01-09 | ||
CN201510013325 | 2015-01-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105777633A true CN105777633A (en) | 2016-07-20 |
Family
ID=56390081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610009817.4A Pending CN105777633A (en) | 2015-01-09 | 2016-01-08 | Tetrahydroisoquinoline derivative and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105777633A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106798742A (en) * | 2017-01-12 | 2017-06-06 | 中国药科大学 | The new application of tetrahydroisoquinoline alkaloid |
WO2018057409A1 (en) * | 2016-09-20 | 2018-03-29 | Merck Sharp & Dohme Corp. | Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as pcsk9 allosteric binders |
CN114516837A (en) * | 2022-01-14 | 2022-05-20 | 山东师范大学 | Nuciferine derivative and preparation method and application thereof |
CN116444522A (en) * | 2023-06-14 | 2023-07-18 | 齐泽(云南)生物科技有限公司 | Curcumin adenine derivative compound |
WO2023165373A1 (en) * | 2022-03-02 | 2023-09-07 | 复旦大学 | Micromolecular pcsk9 protein degradation agent, preparation method therefor, and use thereof |
-
2016
- 2016-01-08 CN CN201610009817.4A patent/CN105777633A/en active Pending
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018057409A1 (en) * | 2016-09-20 | 2018-03-29 | Merck Sharp & Dohme Corp. | Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as pcsk9 allosteric binders |
US11008313B2 (en) | 2016-09-20 | 2021-05-18 | Merck Sharp & Dohme Corp. | Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders |
CN106798742A (en) * | 2017-01-12 | 2017-06-06 | 中国药科大学 | The new application of tetrahydroisoquinoline alkaloid |
CN114516837A (en) * | 2022-01-14 | 2022-05-20 | 山东师范大学 | Nuciferine derivative and preparation method and application thereof |
CN114516837B (en) * | 2022-01-14 | 2023-11-28 | 山东师范大学 | Nuciferine derivative, and preparation method and application thereof |
WO2023165373A1 (en) * | 2022-03-02 | 2023-09-07 | 复旦大学 | Micromolecular pcsk9 protein degradation agent, preparation method therefor, and use thereof |
CN116731005A (en) * | 2022-03-02 | 2023-09-12 | 复旦大学 | PCSK9 small molecular protein degradation agent and preparation method and application thereof |
CN116731005B (en) * | 2022-03-02 | 2024-04-16 | 复旦大学 | PCSK9 small molecular protein degradation agent and preparation method and application thereof |
CN116444522A (en) * | 2023-06-14 | 2023-07-18 | 齐泽(云南)生物科技有限公司 | Curcumin adenine derivative compound |
CN116444522B (en) * | 2023-06-14 | 2023-08-25 | 齐泽(云南)生物科技有限公司 | Curcumin adenine derivative compound |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105753817A (en) | Nitrogen-substituted heterocyclic derivatives and application thereof | |
CN105777632A (en) | Aromatic-ring azacyclo derivatives and application thereof | |
CN105753814A (en) | Substituted nitrogen heterocyclic derivative and application thereof | |
CN105777633A (en) | Tetrahydroisoquinoline derivative and application thereof | |
CN103432133A (en) | Use of nuclear receptor binding agents | |
CN104080455A (en) | Certain chemical entities, compositions, and methods | |
CN102485721A (en) | Substituted 2,3-phthalazinone compounds and application thereof | |
CN106456795A (en) | Targeted therapeutics | |
CN105418601A (en) | Tetrahydrocoptisine derivative and applications thereof | |
RU2557235C1 (en) | Substituted 2-thioxo-imidazolidin-4-one, and spiroanalogues thereof, anticancer active ingredient, pharmaceutical composition, medicinal product, method of treating prostate cancer | |
CN109970745A (en) | Substituted pyrrolo-triazine class compound and its medical composition and its use | |
CA3161373A1 (en) | Compositions and methods for substituted 7-(piperazin-1-yl)pyrazolo[1,5-a]pyrimidine analogs as inhibitors of kras | |
WO2020210229A1 (en) | Degraders of kelch-like ech-associated protein 1 (keap1) | |
CN104788440B (en) | Nicotinic acid derivates and its application | |
CN108440583A (en) | A kind of new boronic acid derivatives and its pharmaceutical composition | |
CN103044395A (en) | Desloratadine-containing amino acid derivative as well as preparation method and application thereof | |
CN105481849A (en) | Tetrahydropalmatine derivative and application thereof | |
CN103360342B (en) | 3-cyano-aniline alkylaryl bridged piperazine derivatives and preparing the application in medicine | |
CN107141284B (en) | Coptisine analog derivative, preparation method, pharmaceutical composition and anticancer usage | |
CN104603133A (en) | Combination therapy for the treatment of cancer and immunosuppression | |
CN105026391B (en) | Crystal formation of compound as mineralocorticoid receptor antagonists and preparation method thereof | |
CN101974016A (en) | Amide compound and preparation method and applications thereof | |
CN103450163A (en) | Indazole compounds, preparation method, and pharmaceutical applications thereof | |
CN106892920A (en) | Aloperine derivative, Preparation Method And The Use | |
CN104926804B (en) | One kind has compound, the preparation method and use of antitumor action |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160720 |
|
WD01 | Invention patent application deemed withdrawn after publication |